СПОСОБ ПОЛУЧЕНИЯ ИЗОБРАЖЕНИЯ КРОВОСНАБЖЕНИЯ МИОКАРДА

Изобретение относится к области медицины, а именно к контрастному агенту структурной формулы:где J представляет собой О; Y представляет собой углерод; K и L независимо выбраны из водорода и C-Салкила; М выбран из водорода, C-Салкилокси или C-Салкила, незамещенных или замещенныхF; Т и U вместе с атомами углерода, к которым они присоединены, образуют шестичленное ароматическое кольцо, которое незамещено или замещеноF; R, Rи Rнезависимо выбраны из водорода и фрагментаF; R, R, Rи Rявляются водородом; n=2; причем по меньшей мере одинF присутствует в структуре указанного контрастного агента и является фрагментом, обеспечивающим изображение. Изобретение также относится к применению указанного контрастного агента, композиции или диагностического набора на его основе для выявления, визуализации и/или мониторинга перфузии миокарда. Группа изобретений обеспечивает расширение арсенала диагностических маркеров для получения изображения кровоснабжения миокарда. 5 н. и 4 з.п. ф-лы, 55 пр.

МАГНЕТИТ В ФОРМЕ НАНОЧАСТИЦ

Изобретение может быть использовано при получении тераностических композиций для гипертермического лечения и/или диагностики опухолей с помощью магнитно-резонансной томографии. Способ полиолового типа для получения наночастиц магнетита включает стадию, на которой указанные наночастицы образуются в растворителе - многоатомном спирте, выбранном из глицерина или пропиленгликоля. Наночастицы магнетита получают из металлического железа и солей Fe, растворимых в указанном многоатомном спирте, при температуре 130-200°C, в присутствии минеральной кислоты в качестве катализатора и воды. Воду берут в молярном соотношении в 1,5-5 раз больше, чем число молей используемой соли Fe. Изобретение позволяет получить наночастицы магнетита однородного размера и повысить значение SAR - удельной мощности поглощения указанных частиц. 3 н. и 3 з.п. ф-лы, 1 ил., 6 табл., 8 пр.

СПОСОБ ПОЛУЧЕНИЯ ЖИДКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ГИПЕРПОЛЯРИЗОВАННЫЙ 13C-ПИРУВАТ, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ГИПЕРПОЛЯРИЗОВАННЫЙ 13C-ПИРУВАТ (ВАРИАНТЫ), ЕЕ ПРИМЕНЕНИЕ (ВАРИАНТЫ), РАДИКАЛ И ЕГО ПРИМЕНЕНИЕ

Изобретение относится к способу получения жидкой композиции, содержащей гиперполяризованный 13С-пируват, включающий: а) образование жидкой смеси, содержащей радикал формулы (I) ! где М представляет собой водород или один эквивалент катиона; и R1, которые являются одинаковыми или разными, каждый представляет собой гидроксилированную и/или алкоксилированную С1-С4-углеводородную группу с прямой или разветвленной цепью, 13С-пировиноградную кислоту и/или 13С-пируват, и замораживание этой смеси; б) усиление поляризации 13С ядер пировиноградной кислоты и/или пирувата в этой смеси посредством ДПЯ (динамическая поляризация ядер); в) добавление физиологически переносимого буфера, который обеспечивает рН в пределах от 7 до 8, и основания к замороженной смеси для ее растворения и для превращения 13С-пировиноградной кислоты в 13С-пируват с получением жидкой композиции или когда на стадии (а) используют только 13С-пируват, добавление буфера к замороженной смеси для ее растворения с получением жидкой ...

РАДИКАЛЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПАРАМАГНИТНЫХ АГЕНТОВ В ПРОЦЕССЕ ДИНАМИЧЕСКОЙ ПОЛЯРИЗАЦИИ ЯДЕР

Изобретение относится к способу динамической поляризации ядер (ДПЯ) соединения, содержащего одну или более чем одну карбоксильную группу, отличающийся тем, что радикал формулы (I) ! ! где М представляет собой один эквивалент катиона щелочного металла; и R1, которые являются одинаковыми или разными, каждый представляет собой C1-С6-алкильную группу с прямой или разветвленной цепью или группу -(CH2)n-X-R2, где n равно 1, 2 или 3; X представляет собой О; и R2 представляет собой С1-С4-алкильную группу с прямой или разветвленной цепью, используют в качестве парамагнитного агента в указанном процессе ДПЯ. Изобретение также относится к новым радикалам, к их применению в качестве парамагнитных агентов. Технический результат - получение новых радикалов формулы (I), которые используют в качестве парамагнитных агентов в процессе ДПЯ. 4 н. и 13 з.п. ф-лы.

СПОСОБ ВИЗУАЛИЗАЦИИ ДЛЯ РАЗЛИЧЕНИЯ ЗДОРОВОЙ ТКАНИ И ОПУХОЛЕВОЙ ТКАНИ

Изобретение относится к области медицины, в частности к онкологии, и может быть использовано для визуализации опухоли с использованием гиперполяризованного 13С-пирувата в качестве магнитно-резонансного визуализирующего агента, позволяющего различать опухолевую ткань и здоровую ткань. Осуществляют: а) получение прямых 13С-МР изображений 13С-пирувата и его 13С-содержащих метаболитов аланина и лактата у субъекта, которому предварительно введена композиция, ! содержащая гиперполяризованный 13С-пируват, б) корректирование лактатного сигнала в отношении количества пирувата и/или аланина с получением взвешенного лактатного относительно пируватного и/или лактатного относительно аланинового изображения. При этом на опухолевую ткань в указанных 13C-изображениях указывает самый высокий лактатный сигнал и/или высокий взвешенный лактатный относительно пируватного и/или лактатный относительно аланинового сигнал. Способ обеспечивает повышение точности визуализации различения здоровой ткани от опухолевой ...

ПРОИЗВОДНЫЕ ИНДОЛА, ПОДХОДЯЩИЕ ДЛЯ ВИЗУАЛИЗАЦИИ НЕЙРОВОСПАЛЕНИЯ

Изобретение относится к соединению Формулы I, которое представляет собой агент визуализации in vivo периферического бензодиазепинового рецептора (PBR):где Q представляет собой водород или фтор; Х представляет собой водород или Салкокси; Y представляет собой S; и R представляет собой Cфторалкил; и где по меньшей мере один атом указанного агента визуализации in vivo Формулы I представляет собой радиоизотоп, подходящий для визуализации in vivo, представляющий собой либо гамма-излучающий радиоактивный галоген, либо позитрон-излучающий радиоактивный неметалл; и где если указанный радиоизотоп является радиоизотопом углерода, то он является карбонильным углеродом. 7 н. и 8 з.п. ф-лы, 2 ил., 1 табл., 12 пр.

СПОСОБ ОПРЕДЕЛЕНИЯ ПОКАЗАНИЙ К МАКСИМАЛЬНО РАДИКАЛЬНОМУ ХИРУРГИЧЕСКОМУ ЛЕЧЕНИЮ БОЛЬНЫХ ХРОНИЧЕСКИМ ПАНКРЕАТИТОМ

Изобретение относится к медицине, хирургии и касается определения показаний к максимально радикальному лечению хронического панкреатита с выраженными изменениями поджелудочной железы (ПЖ). Для этого проводят мультиспиральную компьютерную томографию с болюсным контрастированием с определением среднего показателя соотношения «поздней» фазы на 60-70 сек и «ранней» фазы на 40-45 сек от введения контрастного вещества за вычетом из каждого показателя в единицах Хаунсфильда величины плотности каждого из отделов ПЖ в нативную фазу до введения контрастного вещества. Затем проводят акустическую импульсно-волновую эластометрию с определением скорости распространения сдвиговой волны в ткани ПЖ. Из полученных 8-10 значений скорости распространения сдвиговой волны вычисляют среднее. При среднем показателе соотношения КТ-плотности более 0,97 и среднем показателе скорости распространения сдвиговой волны более 2,14 м/с делают вывод о наличии показаний к максимально радикальной операции. Способ обеспечивает ...

ПРОИЗВОДНЫЕ БИЦИКЛОПОЛИАЗАМАКРОЦИКЛОФОСФОНОВЫХ КИСЛОТ ИЛИ ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СПОСОБ ИХ ПОЛУЧЕНИЯ

Использование: в качестве контрастных агентов в магниторезонансной визуализации. Продукты: производные бициклополиазамакроциклофосфоновых кислот формулы I, где R - группа - (C)n (x) (y) - T, x и y - H или COOH, п - целое число 1,2 или 3, T - COOH, - C6H4R4 или P (O) (R1) OH, R1 - OH или -O-(C1 - C5)алкил, R4 - NO2 или NH2, при условии, что один T должен быть группой P(O) (R1)OH, или их фармацевтически приемлемые соли. Реагент 1: соединение формулы 1, в которой по крайней мере одна группа R представляет собой водород. Реагент 2: фосфористая кислота или ее эфир. Условия реакции: в среде растворителя в присутствии формальдегида. 2 с. и 18 з.п.ф-лы, 4 табл. соединение формулы I.

СПОСОБ ОТБОРА ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ НА ПРОВЕДЕНИЕ ПРОЦЕДУРЫ СЦИНТИГРАФИИ МИОКАРДА ДЛЯ ДИАГНОСТИКИ ХРОНИЧЕСКОГО ЛАТЕНТНОГО МИОКАРДИТА

Изобретение относится к медицине, кардиологии, лучевой диагностике. Для отбора пациентов с фибрилляцией предсердий (ФП) на проведение процедуры сцинтиграфии миокарда при диагностике хронического латентного миокардита проводят клинико-анамнестическое и лабораторно-инструментальное обследование. При наличии комплекса диагностических признаков: жалобы на одышку инспираторного характера, боль в области сердца, не связанная с физической нагрузкой, связь появления ФП с перенесенным инфекционным заболеванием, повышенный уровень интерлейкина-6 в сыворотке крови более 5 мг/мл, а также зон постконтрастного усиления на отсроченных Т1-взвешенных изображениях по данным контрастусиленной магнитно-резонансной томографии сердца, назначают сцинтиграфию миокарда сTc-пирофосфатом. Способ обеспечивает повышение точности диагностики хронического латентного миокардита у пациентов с ФП при снижении лучевой нагрузки и стоимости обследования данной группы пациентов. 1 ил., 2 табл., 1 пр.

КОНТРАСТНЫЕ АГЕНТЫ ДЛЯ ОТОБРАЖЕНИЯ ПЕРФУЗИИ МИОКАРДА

... 1. Способ получения изображения кровоснабжения миокарда, включающий введение пациенту контрастного агента, который содержит фрагмент, обеспечивающий изображение, и соединение, выбранное из дегелина, пиридабена, пиридимифена, тебуфенпирада, феназаквина, аналога дегелина, аналога пиридабена, аналога пиридимифена, аналога тебуфенпирада и аналога феназаквина, и сканирование пациента с применением диагностического изображения. 2. Способ по п.1, отличающийся тем, что фрагмент, обеспечивающий изображение, представляет собой радиоизотоп для ядерно-магнитной томографии, парамагнитные фрагменты для применения в MRI, эхогенную группу для ультразвукового исследования, флуоресцентную группу для применения при получении флуоресцентного изображения или светоактивную группу для применения при получении оптического изображения. 3. Контрастный агент, содержащий фрагмент, обеспечивающий изображение, и соединение, выбранное из дегелина, пиридабена, пиридимифена, тебуфенпирада, феназаквина, аналога дегелина ...

КОНТРАСТНЫЕ ВЕЩЕСТВА ДЛЯ ДЕТЕКЦИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

... 1. Соединение для диагностики рака предстательной железы у человека или животного, которое содержит, по меньшей мере, один направляющий модуль и, по меньшей мере, один детектируемый компонент, где направляющий модуль способен к взаимодействию со специфическим молекулярным маркером рака предстательной железы, выбранным из группы, состоящей из DD3PCA3 (DD3) и теломеразной обратной транскриптазы (TERT). ! 2. Соединение по п.1, где направляющий модуль выбран из группы, содержащей антитела, полипептиды, пептиды, пептидомиметики и низкомолекулярные органические соединения. ! 3. Соединение по п.1 или 2, где специфический маркер рака предстательной железы представляет собой TERT. ! 4. Соединение по п.3, где направляющий модуль представляет собой низкомолекулярный ингибитор TERT, предпочтительно выбранный из группы, состоящей из 3'-азидо-2',3'-дидезокситимидина, дизамещенных антрахинонов, флуоренонов, акридинов, соединений на основе тетрациклов, G-квадруплексных ингибиторов на основе порфирина и ...

Способ получения модифицированных кристаллов магнетита

Изобретение относится к области неорганической химии и касается способа получения модифицированных кристаллов магнетита FeO, содержащих на поверхности флуоресцентный краситель, что дает возможность визуализировать и отслеживать их поведение как в живой клетке, так и в живом организме in vivo. Такие кристаллы могут найти применение в качестве средств доставки лекарств и Т2-контрастных агентов. Способ получения модифицированных кристаллов магнетита включает смешение 138 мас. ч. кристаллов магнетита и 1 мас. ч. смеси холестерина, 1,2-дистеароил-sn-глицеро-3-фосфохолина, 1,1'-(2-(4-(2-((2-(бис(2-гидроксидодецил)амино)этил)(2-гидроксидецил)амино)этил)пиперазин-1-ил)этилазанедиил)дидодекан-2-ола и 1,2-димиристоил-sn-глицерометокси(полиэтиленгликоля)-2000, взятых в массовом соотношении 15:7:75:3, соответственно, вначале с 60000 мас. ч. хлороформа, затем с 82240 мас. ч. N-метил-2-пирролидона, обработку смеси ультразвуком, удаление хлороформа и добавление в нее воды с последующим диализом полученной ...

Система визуализации и способ получения систем визуализации на основе наночастиц и их применение для повышения эффективности радиологических методов исследования злокачественных новообразований

Группа изобретений относится к области наномедицины, в частности к способу получения композиции из наночастиц и применению такой композиции в области диагностики злокачественных новообразований. Способ получения композиции для использования в системах визуализации при радиологических методах исследования включает синтез наночастиц карбоната бария, при этом сначала получают следующие растворы: полиакриловый кислоты в растворе этиленгликоля; карбоната натрия в растворе этиленгликоля; хлорида бария в растворе этиленгликоля. Смешивают раствор полиакриловой кислоты с раствором карбоната натрия, перемешивают, доводя при этом рН раствора до 3-5; смешивают раствор полиакриловой кислоты с раствором хлорида бария и перемешивают, доводя при этом рН раствора до 3-5. Смешанный раствор полиакриловой кислоты/карбоната натрия добавляют в перемешивающийся раствор полиакриловой кислоты/хлорида бария по каплям в течение 1-10 минут, конечный раствор перемешивают в течение 0,5-2 часов, после чего проводят отмывку ...

Способ получения наночастиц магнетита, эпитаксиально выращенных на наночастицах золота

Изобретение относится к области неорганической химии и касается способа получения наночастиц магнетита (FeO), эпитаксиально выращенных на наночастицах золота, которые могут быть использованы в магнитно-резонансной томографии в качестве контрастного агента, в магнитной сепарации, магнитной гипертермии, адресной доставке лекарств при помощи внешнего магнитного поля. Способ получения наночастиц магнетита, эпитаксиально выращенных на наночастицах золота, включает нагрев до 120°С в атмосфере инертного газа при перемешивании смеси дифенилового эфира, олеиновой кислоты, олеиламина и 1,2-гексадекандиола, введение в смесь пентакарбонила железа, выдерживание полученной смеси с последующим введением раствора, содержащего смесь тригидрата золотохлористоводородной кислоты и олеиламина в дифениловом эфире, предварительно выдержанного в атмосфере инертного газа, повторный нагрев при температуре 250-260°С, выдерживание нагретой смеси при температуре 250-260°С в течение 25-30 мин, ее последующее охлаждение ...

СПОСОБ ОПРЕДЕЛЕНИЯ СТЕПЕНИ ФИБРОЗА ПЕЧЕНИ

Изобретение относится к области медицины, а именно гепатологии, и может использоваться для определения степени фиброза печени. Пациенту выполняютС-метацетиновый дыхательный тест. Используя значения кумулятивной дозыС на 10-й, 20-й и 30-й минутах указанного теста, определяют степень фиброза печени по формуле: N=1a+2b+10c, где - N - сумма баллов, а - коэффициент, рассчитываемый из кумулятивной дозыС за 10 минут в % (CUM10), b - коэффициент, рассчитываемый из кумулятивной дозыC за 20 минут в % (CUM20), с - коэффициент, рассчитываемый из кумулятивной дозыС за 30 минут в % (CUM30). При этом если CUM10<1,00%, то а=1, если CUM10>1,00%, то а=0. Если CUM20<2,50%, то b=1, а если CUM20>2,50%, то b=0. Если CUM30<5,65%, то с=1, если CUM30>5,65%, то с=0. При значении N=0, определяют степень фиброза печени как F0, соответствующую отсутствию портального фиброза. При значении N=1-3 определяют степень фиброза печени как F1-2, соответствующую наличию портального фиброза без септ и с небольшим количеством ...

Способ исследования функции почек при мультиспиральной компьютерной томографии

Изобретение относится к медицине, а именно к урологии, нефрологии и лучевой диагностике, и может быть использовано для исследования функции почек при мультиспиральной компьютерной томографии. Проводят трехмерную мультиспиральную компьютерную томографию с внутривенным контрастированием. Осуществляют нативную, артериальную, венозную, экскреторную фазу транспорта контрастного вещества в почках. Далее определяют в почках зоны интереса, в качестве которых по данным 3D-моделирования выделяют объемы коркового и мозгового вещества каждой почки в каждую из фаз. Измеряют в объемах коркового и мозгового вещества каждой почки величины плотности содержания контрастного вещества в единицах Хаунсфилда (HU). Вычитают из величины плотности содержания контрастного вещества объемов коркового и мозгового вещества в артериальную фазу показатели в нативную фазу. После этого вычисляют их интегралы и получают величины плазмотока раздельно в процентном отношении для каждой почки. Далее из интеграла плотности содержания ...

Поликомпонентная наноразмерная система для диагностики и терапии новообразований

Изобретение может быть использовано в медицине. Поликомпонентная наноразмерная система для диагностики и терапии новообразований состоит из ядра, сформированного из диоксида кремния, диоксида титана, диоксида циркония или их композитов, внутреннего слоя, содержащего оксид меди, диоксид марганца, двойной оксид железа или их композитов, внешнего слоя, содержащего металлические наночастицы серебра, золота или их биметаллические частицы, и биологически активные молекулы - биомаркеры. Изобретение позволяет получить поликомпонентную наноразмерную систему, имеющую структуру «ядро-оболочка», содержащую сферические агрегативно устойчивые монодисперсные частицы, в качестве контрастного агента для магнитно-резонансной и компьютерной томографии и в качестве основы для препаратов адресной доставки лекарственных средств в противоопухолевой терапии. 6 ил., 3 пр.

СПОСОБ ВЫЯВЛЕНИЯ ОЧАГОВ ВОСПАЛЕНИЯ С ПОМОЩЬЮ МЕТОДИКИ ПОЛИОРГАННОЙ СЦИНТИГРАФИИ

Изобретение относится к области медицины, а именно, к радионуклидной диагностике и может быть использовано для выявления очагов воспаления с помощью методики полиорганной сцинтиграфии. Проводят забор крови не менее 250-400 мл в первый стерильный пакет, который подвергают центрифугированию со скоростью 800 об/мин в течение времени, необходимого для осаждения эритроцитов. Переводят во второй пакет полученную в первом пакете обогащенную лейкоцитами надосадочную плазму. Осуществляют центрифугирование содержимого второго пакета со скоростью 1300 об/мин в течение времени, необходимого для получения аутолейкоцитов. Далее надосадочную плазму из второго пакета переводят в третий пакет, а эритроциты из первого пакета внутривенно возвращают пациенту. Добавляют радиофармпрепарат (РФП) в количестве 3-5 мл в аутолейкоциты, оставшиеся во втором пакете. Полученную клеточную взвесь инкубируют в течение 8-10 мин. К ней добавляют плазму из третьего пакета в количестве 10-20 мл с последующим центрифугированием ...

ПРОИЗВОДНЫЕ ИНДОЛА, ПОДХОДЯЩИЕ ДЛЯ ВИЗУАЛИЗАЦИИ НЕЙРОВОСПАЛЕНИЯ

... 1. Агент визуализации in vivo Формулы I: ! ! или его соль или сольват, где: ! Q представляет собой водород или фтор; ! Х представляет собой водород, фтор, бром, йод, гидрокси, C1-4алкил, C1-4галогеноалкил, C1-4алкокси или C1-4алкиламид; ! Y представляет собой S; и ! R представляет собой водород, C1-6алкил или C1-6фторалкил; ! и где по меньшей мере один атом указанного агента визуализации in vivo Формулы 1 представляет собой радиоизотоп, подходящий для визуализации in vivo, представляющий собой либо гамма-излучающий радиоактивный галоген либо позитрон-излучающий радиоактивный неметалл; и где, если указанный радиоизотоп является радиоизотопом углерода, то он является карбонильным углеродом; при условии, что Q или Х оба не являются водородом. ! 2. Агент визуализации in vivo по п.1, где Х представляет собой водород или C1-4алкокси. ! 3. Агент визуализации in vivo по п.1, где R представляет собой водород, C1-4алкил или C1-4фторалкил. ! 4. Агент визуализации in vivo по п.3, где R представляет ...

КОНЪЮГАТЫ ЛИГАНДА С НЕСКОЛЬКИМИ ЛЕКАРСТВЕННЫМИ СРЕДСТВАМИ

... 1. Конъюгат для доставки лекарственного средства, связывающий рецептор, включающий: ! (a) связывающую рецептор группу; ! (b) поливалентный линкер; и ! (c) два или более лекарственных средства, или их аналоги или производные; ! где связывающая рецептор группа ковалентно связана с поливалентным линкером; ! два или более лекарственных средства, или их аналоги или производные, ковалентно связаны с поливалентным линкером; и ! поливалентный линкер включает один или несколько компонентов, выбранных из группы, состоящей из спейсерных линкеров, обеспечивающих высвобождение линкеров и линкеров с гетероатомом, и их сочетаний. ! 2. Конъюгат для доставки лекарственного средства, связывающий рецептор для витамина формулы: ! ! где (L) выбран из группы, состоящей из (lS)a, (lH)b и (lr)c и их сочетаний; где (lr) представляет собой обеспечивающий высвобождение линкер, (lS) представляет собой спейсерный линкер, и (lH) представляет собой линкер с гетероатомом; ! (B) представляет собой связывающую рецептор ...

КАЛИБРОВКА СИСТЕМ МРТ С ИСПОЛЬЗОВАНИЕМ ЗАРАНЕЕ ЗАДАННЫХ КОНЦЕНТРАЦИЙ ИЗОТОПОВ 19F В КАЧЕСТВЕ ОПОРНОГО ЗНАЧЕНИЯ

СПОСОБ ПОЛУЧЕНИЯ ГАММА-АМИДОВ ГЛУТАМОВОЙ КИСЛОТЫ

... 1. Способ получения γ-амидов глутамовой кислоты в соответствии со следующей схемой: где R4представляет аминозащитную группу; R5 представляет неразветвленный или разветвленный С1-С10алкил или арил; R2 и R3независимо представляют атом водорода, разветвленный или неразветвленный С1-С20 алкил, незамещенный или замещенный арильными группами, или указанные группы образуют С3-С10цикл.

PARAMAGNETISCHE DIAGNOSTISCHE ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG

Makrocyclische Chelatisierungsmittel und daraus hergestellte Chelate.

Para- und diamagnetische perfluorhaltige Verbindungen enthaltende galenische Formulierungen, deren Herstellung und Verwendung

GEM-DIHALO-1,8-DIAMINO-4-AZA-OKTANE.

METALLIERUNG VON MAKROZYKLEN MIT 2,4-DICARBONYL-METALLKOMPLEXEN

Contrasting compositions

Tumour-targeted theranostic

IMPROVEMENTS IN AND RELATING TO MAGNETIC RESONANCE IMAGING

PHYSIOLOGICALLY TOLERABLE METAL COMPLEX SALTS FOR USE IN NMR DIAGNOSIS

IRON-CONTAINING PREPARATION FOR USE AS NMR CONTRAST MEDIUM

Iron-contg. prepn used as an NMR contrast medium contains as essential components (1) an iron cmpd (01. - 10% wt, (0.5-5%) (as Fe)); (2) sodium and/or bi-carbonate (8 - 60%, (20-45%), and esp. 22-26% sodium carbonate or 20-45% sodium bicarbonate); (3) a neutralising agent (10 -70% (20-50%) and esp. 30-40%). Potassium carbonate may also be present as a preservative (0.2-12% wt, (0.3-3%) and esp. 0.4-1%). The prepn. is pref. an aq soln of pH 3- 5.5 (3.5 -4.6) but may be made up as dispersion for dilution or as tablets for dissolution before use.

Contrasting compositions for magnetic resonance imaging comprising a complex of ethylene diamine disuccinic acid and one or more paramagnetic metal ions

The invention relates to contrasting compositions comprising a complex of one or more selected metal ions (viz paramagnetic metal ions, eg a Gd ion and/or a Mn ion) and a specific complexing agent (viz ethylene diamine disuccinic acid). The invention also relates to the use of these complexes for preparation of a contrasting agent for use in MRI methods. The invention also relates to methods of preparation of such contrasting compositions.

Improvements in and relating to magnetic resonance imaging

Compound

Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.

The present invention provides a method of treating Alzheimer's disease using a medicament derived from a novel compound of formula I, Also provided is a treatment for inhibiting the aggregation of amyloid proteins using a medicament derived from a compound of Formula I and a procedure for imaging amyloid deposits using isoindoline derived medicaments.

Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.

Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

MANGANESE COMPOSITIONS AND PROCEDURES FOR MRI

DIAGNOSTIKA FOR THE EXOKRINE FUNCTION OF THE PANCREAS

DIAGNOSTIC MEANS

DERIVATISIERTE DTPA COMPLEXES, THESE CONNECTIONS ABSTENTION PHARMACEUTICAL MEANS, YOUR USE AS NMR AND ROENTGEN CONTRAST MEANS AND PROCEDURE FOR THEIR PRODUCTION

METAL COMPLEX CONNECTIONS

QUALITY INCREASE OF MR-PICTURES OF BONES AND SIMILAR FABRIC OF MEANS OF PARAMAGNETIC CATION COMPLEXES AND POLYPHOSPHONATLIGANDEN

MAKROCYCLI CHELATISIERUNGSMITTEL AND FROM IT MANUFACTURED CHELATE.

CONTRAST MEANS FOR THE REPRESENTATION OF THE LIVER GALLENSYSTEMS MEANS NMR KONTRASTMITTEL

POLYAZAMAKROCYCLI CONNECTIONS FOR INTEGRATION METAL IONS

A BINUKLEAREN A COMPLEX ABSTENTION DIAGNOSTICS COMPOSITIONS, PROCEDURE FOR THEIR PRODUCTION AND USE IN MAGNETIC NUCLEAR RESONANCE IMAGING

PROCEDURES FOR THE INCREASED SAFETY OF METAL LIGANDCHELATEN AS X-RAY CONTRAST MEANS.

PERFLUORO T BUTYL CONTAINING CONNECTIONS TO THE USE IN FLUOR-19-NMR AND/OR MRI

CASCADE-POLYMER-BOUND COMPLEXING AGENTS, THEIR COMPLEXES AND KONJUGATE, PROCEDURES FOR YOUR PRODUCTION AND THESE CONTAINING PHARMACEUTICAL MEANS.

CONTRAST MEANS FOR MAGNETIC RESONANCE ILLUSTRATION OF THE SMALL INTESTINE AND THE HEPATOBILIAREN THE SYSTEM.

1,4,7,10-TETRAAZACYCLODODECAN-DERIVATE.

FULLERENE COMPOSITIONS FOR M.R.I.

HYDRAULIC XY ARYL METALLCHELATE FOR PICTURE FIGURATION TO THE NMR DIAGNOSIS

DTPA MONOAMIDE ONE, THESE CONNECTIONS ABSTENTIONS PHARMACEUTICAL MEANS, YOUR USE AND PROCEDURE FOR THEIR PRODUCTION.

DIPYRIDOXYL PHOSPHATE AS MAGNETIC NUCLEAR RESONANCE PICTURE GIVING MEANS.

5- OR 6-RING-ENTHALTENDE MAKROCYCLI POLYAZA CONNECTIONS, PROCEDURES FOR YOUR PRODUCTION AND THESE CONTAINING PHARMACEUTICAL MEANS.

POLYETHERSUBSTITUIERTE TUMOR MEANS.

NMR KONTRASTMITTEL.

MEHRZÄHNIGE METAL CHELATIERENDE CONNECTIONS

PROCEDURE FOR THE PRODUCTION OF 1,4,7,10 - TETRAAZADODECAN-1,4-DIESSIGSÄUREDERIVATEN

PROCEDURE FOR the PRODUCTION OF PICTURES AND SPECTRA THAT EXTRACELLULÄREN pH USING the MAGNETIC RESONANCE ASSISTANCE OF 1H AND 19F ABSTENTION EXTRINSI INDIKATORREN

PROCEDURE, REAGENTS AND TEST KITS FOR THE PROOF OF SUBPOPULATIONEN OF BIOLOGICAL SUBSTANCES

SUBSTITUTED PORPHYRINEN

ANTAGONIST THE PANELS OF THE ACTIVATING FACTOR

CALCIUM COMPLEX OF (4R) - 4-BIS (CARBOXY KAPPA.O) METHYL AMINO-.KAPPA.N-6,9-BIS (CARBOXY

WITH FLUORINE MARKED ANTHRACYCLIN AND - ANTHRACYCLINON DERIVATIVES

Alkyl, alkenyl and alkynyl chrysamine g derivatives for the antemortem diagnosisof alzheimer's disease and (in vivo) imaging and prevention of amyloid depositi on

Composition for removing noise from MRI and pad using same

The present invention relates to a composition for removing noise from an MRI, including a compound containing a hydrogen bond, and a pad using the same. The present invention has the advantages of naturally generating high signals through indirect energy exchange due to magnetization of the hydrogen bond, and activating an image of tissue which was unable to be embodied as an image due to noise generated by metal. Also, the composition according to the present invention can be applied by a non-invasive method unlike an MRI contrast agent, and thus there is no problem that will cause side effects in the human body, and the composition is not toxic and thus is safe. In addition, the composition is used in the manner of covering an area requiring diagnosis or being attached to an MRI apparatus, and thus has the advantages of improving images of a relatively wide range, and obtaining more accurate image information than restoration of a distorted image by a program. At the same time, the composition ...

PARAMAGNETIC COMPLEX SALTS, THEIR PREPARATION AND THEIR USE IN NMR-DIAGNOSTICS

AMIDE COMPLEXES FOR X-RAY AND NMR PROCEDURES

Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles

OF THE DIsCLOSURE The present disclosure provides functionalized magnetic nanoparticles (MNPs) comprising a functional group that binds to p-amyloid deposits and/or neurofibrillary tangles. The present disclosure provides compositions comprising the functionalized MNPs, and methods of using the functionalized MNPs in imaging -amyloid deposits and neurofibrillary tangles.

Synthesis of polyazamacrocycles with two or more side-chain chelating groups

METHODS, REAGENTS AND TEST KITS FOR DETERMINATION OF SUBPOPULATIONS OF BIOLOGICAL ENTITIES

Diagnostic composition comprising plasma cations having superior safety profile

The present invention relates to a new diagnostic X-ray composition which exhibits a superior cardiac safety profile. The composition comprises a non-ionic iodinated dimer in a pharmaceutically acceptable carrier. More particularly, the invention provides a diagnostic composition comprising a Compound I, a pharmaceutically acceptable carrier, and dissolved therein a sodium compound and a calcium compound providing a sodium ion concentration of 40-50 mM and a calcium ion concentration of 0.1-0.7 mM. The invention also relates to methods of imaging using such diagnostic compositions.

Bioconjugates of manganese complexes and their application ascatalysts

Magnetic resonance blood pool agents

Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders

The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE 10). In particular, the invention relates to combinations of 1-aryl-4- methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051342 and in WO 2011/110545. The invention is also directed to pharmaceutical compositions comprising such combinations, to processes for preparing such compositions, to the use of PDE2 inhibitors, in particular of 1- aryl-4-methyl- [1,2,4]triazolo[4,3-a]-quinoxaline derivatives for the potentiation of said PDE10 inhibitors, and to the use of said PDE10 inhibitors for the potentiation of the effect of said PDE2 inhibitors, in particular, 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives ...

Multi-site metal chelating agents

DETERMINING TEMPERATURE AND PH USING LMR-A NON-INVASIVE TECHNIQUE

Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles

PHYSICALLY AND CHEMICALLY STABILIZED POLYATOMIC CLUSTERS FOR MAGNETIC RESONANCE IMAGE AND SPECTRAL ENHANCEMENT

NMR CONTRAST AGENTS

Contrast agents for mr diagnosis

Method for increasing nuclear magnetic resonance signals in living biological tissue

SYSTEMS AND METHODS FOR PRODUCING HYPERPOLARIZED MATERIALS AND MIXTURES THEREOF

The present disclosure provides various methods and systems for manufacture, transport and delivery of material including highly polarized nuclei that is in a hyperpolarized state.

MAGNETITE IN NANOPARTICULATE FORM

The present invention relates to a process for the polyol-type synthesis of nanoparticulate magnetite starting from mixtures of Fe0 and Fe1III in the presence of a mineral acid. The magnetite particles obtainable from the process have uniform size characteristics and have even presented higher SAR (Specific Absorption Rate) values than those of magnetosomes.

METHOD FOR ENHANCING THE SAFETY OF METAL-LIGAND CHELATES AS MAGNETIC RESONANIS IMAGING AGENTS AND X-RAY CONTRAST AGENTS

METHOD FOR ENHANCING THE SAFETY OF METAL-LIGAND CHELATES AS MAGNETIC RESONANTS IMAGING AGENTS AND X-RAY CONTRAST AGENTS Paramagnetic chelates, as for example, Gadolinium diethylenetriaminepentaacetic acid (DTPA), manganese, ethylenediaminetetraacetic acid (EDTA), and others used as magnetic resonance imaging contrast agents are more toxic acutely when injected in high concentration or at rapid rates. The use of effective amounts of calcium in the form of, calcium chloride, calcium gluconate, or balanced salt solutions substantially reduces this toxicity without the need to add additional ligand.

METHOD OF CARDIAC IMAGING WITH THE USE OF HYPERPOLARIZED 13 C-PYRUVATE

DRUGS FOR THERAPEUTIC USE ENABLING NUCLEAR MAGNETIC RESONANCE DIAGNOSIS BY SCALAR BOND

... ▓▓▓Drugs for therapeutic use characterized by containing a compound which carries ▓in its structure at least one member selected from among -17OH, -14NH and -▓33SH, wherein the above 17O, 14N or 33S exerts a relaxation effect on the ▓proton bonded thereto and the relaxation effect is transported through the ▓exchange of a proton in a vital component of a target organ or tissue by the ▓above-mentioned proton, thus enabling detection by nuclear magnetic resonance. ▓The effective circulation or distribution of such a physiologically acceptable ▓therapeutic drug in the target organ or tissue in vivo where it is needed can ▓be externally detected by the nuclear magnetic resonance method before the ▓administration of a remedy to each patient or simultaneously therewith.▓ ...

NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING CONTAINING SAME, AND LIGAND COMPOUND

Provided is a novel nanoparticle, a contrast agent for magnetic resonance imaging containing the same, and a ligand compound used for the production of the nanoparticle. The present invention relates to a nanoparticle including: a metal particle containing ferric oxide; and a ligand represented by formula (3), where the ligand is bonded to a metal atom on the surface of the metal particle. (In the formula, m is an integer of 1 to 4, and the broken line represents a coordinate bond with a metal atom on the metal particle surface.) ...

COMPRESSED SOLID COMPOSITION FOR MRI

The present invention relates to a compressed solid composition for MRI comprising a physiologically acceptable manganese (II) compound, its preparation and use for preparing an oral solution.

NITROIMIDAZOLE SUBSTITUTED PORPHYRIN COMPLEX

... ▓▓▓A drug which is a porphyrin derivative having a nitroimidazole compound bonded ▓thereto. It takes advantage of the affinity of the porphyrin derivative for ▓cancers. It functions to form an image in magnetic resonance imagination (MRI) ▓and further has a sensitizing function for radiotherapy. Also provided is a ▓porphyrin compound which is applicable to a treatment with a DDS and is free ▓from light toxicity. Specifically, the compound is a porphyrin complex ▓represented by formula (I) or a pharmacologically acceptable salt thereof. ▓[wherein R1 and R2 each represents -CH=CH2, -CH(CH3)OH, or -CH(CH3)O-(CH2)n-NH-▓Ra (Ra represents hydrogen or a group represented by formula (II) and n and m ▓each is an integer of 2 or 3); R3 represents hydrogen or -CO(CH2)m-CO2H; and M ▓represents a transition metal selected among manganese, iron, cobalt, and ▓copper].▓ ...

IMAGING CORRELATES OF NEUROGENESIS WITH MRI

This invention provides a method for treating a mammalian subject afflicted with a disorder associated with reduced neurogenesis in the subject's hippocampal dentate gyrus which comprises administering to the subject a therapeutically effective amount of a compound which increases cerebral blood volume in the subject's hippocampal dentate gyrus by a percentage greater than that by which it increases the cerebral blood volume in the subject's hippocampal CAl region, thereby treating the subject.

METHODS OF TREATING BRAIN DISORDERS OR IDENTIFYING BIOMARKERS RELATED THERETO

The present disclosure relates in part to methods of treating cognitive disorders and/or identifying biomarkers.

USE OF GELSOLIN TO TREAT MULTIPLE SCLEROSIS AND TO DIAGNOSE NEUROLOGIC DISEASES

The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.

PERYLENEQUINONE DERIVATIVES AND USES THEREOF

The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.

Method for the Generation of Nuclear Hyper-Antipolarization in Solids Without the Use of High Magnetic Fields or Magnetic Resonant Excitation

A method of inducing nuclear spin hyper-antipolarization in a solid material is disclosed and described. The solid material can be subjected to an ultralow temperature and a magnetic field. The solid material can include donor nuclei and a carrier material while the material also has both a nuclear spin and an electron spin which are coupled sufficiently to allow an Overhauser effect. The solid material can be subjected at the ultralow temperature to a light source for a time sufficient to induce a substantial nuclear spin antipolarization in the solid material and form a nuclear spin hyper-antipolarized material. The ultralow temperature and light source are controlled so as to be sufficient to drive a non-equilibrium nuclear Overhauser effect of hyperfine coupled electron and nuclear spins. The resulting nuclear spin hyper-antipolarized material can be used for a variety of applications such as medical imaging and quantum computing. These materials can be readily formed relatively quickly and are generally stable at room temperatures.

Optical imaging agents

The present invention relates to a method of in vivo optical imaging, of the margins around tumours, which comprises an optical imaging contrast agent. The optical imaging agents comprise conjugates of near-infrared dyes with synthetic polyethylene glycol (PEG) polymers having a molecular weight in the range 15-45 kDa. Also disclosed are optical imaging contrast agents, pharmaceutical compositions and kits.

Formation and uses of europium complexes

The present invention provides a method of forming an oxidatively-stable aqueous Eu(II) complex by synthesizing ligands that coordinate to large, soft, electron rich metals like Eu(II). The invention also provides an oxidatively stable aqueous Eu(II) complex. The complex can be used for a variety of purposes some of which include, but are not limited to, in paramagnetic chemical exchange saturation transfer, as a medical diagnostic, as a semiconductor, and for use in forming materials.

METHOD AND SYSTEM FOR QUANTITATIVE RENAL ASSESSMENT

Method and system embodiments of the present invention employ computational analysis tools running on one or more computer systems to quantitatively analyze MRI data from patients in order to both assess various functional parameters and characteristics of a patient's kidney, as well as to provide an electronic display device interconnected with the one or more computer systems, and accessible visualization of the quantitative assessment to facilitate diagnosis of various types of kidney abnormalities and pathologies. 1. A quantitative-organ-assessment system comprising:(a) a computer system;(b) a time series of MRI images obtained in the absence and presence of an MRI contrast-enhancing substance, stored as a dataset within the computer system, wherein the dataset comprises intensities associated with voxels at each time point in the time series of MRI images; and (i) compressing the dataset to fewer dimensions,', '(ii) partitioning voxels within the dataset into clusters, each cluster containing voxels with similar time-intensity curves, and', '(iii) computing functional characteristics and parameters of the organ from aggregate intensity-versus-time characteristics of the voxels within the clusters., '(c) a quantitative-organ-assessment component, executing on one or more processors of the computer system, which generates an assessment of the organ imaged in the time series of MRI images by2. A quantitative-renal-assessment system comprising:(a) a computer system;(b) a time series of MRI images obtained in the absence and presence of an MRI contrast-enhancing substance, stored as a dataset within the computer system, wherein the dataset comprises intensities associated with voxels at each time point in the time series of MRI images; and (i) compressing the dataset to fewer dimensions,', '(ii) partitioning voxels within the dataset into clusters, each cluster containing voxels with similar time-intensity curves, and', '(iii) computing functional characteristics ...

SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE

Alkyl cyanoacrylate compositions and methods for making those compositions, utilizing high purity monomeric starting materials, formed into more viscous oligomers, and combined with a plasticizer and inhibitor to provide a single-container, storage stable medical cyanoacrylate. 1. A medical grade composition suitable for application to or in the human body , comprising a mixture of:(a) a polymerizable alkyl cyanoacrylate oligomer, wherein said polymerizable alkyl cyanoacrylate oligomer has a viscosity of from 10 centipoise to 30 centipoise;(b) at least one polymerization inhibitor;(c) a contrast agent; and(d) a plasticizer,wherein said composition is sealed in a single container and is stable for more than one month at room temperature, and is adapted to polymerize in vivo.2. The composition of claim 1 , wherein the polymerizable alkyl cyanoacrylate oligomer is selected from the group consisting of 2-hexyl cyanoacrylate oligomer claim 1 , n-hexyl cyanoacrylate oligomer claim 1 , pentyl cyanoacrylate oligomer claim 1 , heptyl cyanoacrylate oligomer claim 1 , and octyl cyanoacrylate oligomer.3. The composition of claim 1 , wherein the polymerizable alkyl cyanoacrylate oligomer is n-hexyl cyanoacrylate oligomer.4. The composition of claim 1 , wherein the inhibitor is selected from the group consisting of 4-methoxyphenol claim 1 , 2 claim 1 ,6-di-tert-butyl-4-methylphenol claim 1 , hydroquinone claim 1 , phosphoric acid claim 1 , sulfur dioxide (SO) claim 1 , and any combination thereof.5. The composition of claim 4 , wherein the inhibitor is a mixture of 4-methoxyphenol claim 4 , 2 claim 4 ,6-di-tert-butyl-4-methylphenol claim 4 , and sulfur dioxide.6. The composition of claim 1 , wherein the plasticizer is tri-n-butyl O-acetylcitrate.7. The composition of claim 1 , wherein the contrast agent is selected from the group consisting of gold claim 1 , platinum claim 1 , tantalum claim 1 , titanium claim 1 , tungsten claim 1 , barium sulfate claim 1 , and combinations ...

Nanoparticles based on gadoliium coordination polymers as highly sensitive t1 mri contrast agents

An agent for imaging of a biological system or delivering drugs to a biological system including one or more nanoparticles formed of at least one gadolinium coordination polymer.

Therapeutic Angiogenesis for Treatment of the Spine and Other Tissues

Methods for the diagnosis and treatment of ischemic spinal conditions, degenerative disc disease, back pain and/or other tissue pathologies. Patients with ischemic spine disease can be categorized into subsets that are deemed to have potential to respond to therapy. In particular, therapies are disclosed which involve stimulation of neovascularization so as to increase perfusion of spinal and other anatomies. 1. A method of diagnosing a patient with an ischemic spinal disorder , comprisingobtaining electronic image data of one or more vertebral bodies of the patient;identifying one or more regions of interest in the electronic image data, the one or more regions of interest including electronic image data of at least a portion of an intravertebral microcirculation proximate to an intervertebral endplate;analyzing the one or more regions of interest to obtain one or more perfusion measurements within each region of interest;comparing the one or more perfusion measurements with a predetermined perfusion value; anddiagnosing said patient with said ischemic spinal disorder wherein said one or more perfusion measurements is below said predetermined perfusion value.2. A method of treating a patient having an ischemic spinal disorder comprising:obtaining one or more images of at least a portion of a spine of the patient;analyzing the one or more images with a computing system to quantify a localized perfusion of the intravertebral microcirculation proximate to one or more endplates of one or more intervertebral discs of the patient's spine;identifying at least one intravertebral location where the quantified localized perfusion of the intravertebral circulation indicates hypoperfusion of the intravertebral circulation; andtreating the patient by injecting an angiogenesis inducing compound proximate to the at least one intravertebral location where the quantified localized perfusion of the intravertebral circulation indicates hypoperfusion of the intravertebral circulation. ...

USE OF GELSOLIN TO TREAT MULTIPLE SCLEROSIS AND TO DIAGNOSE NEUROLOGIC DISEASES

The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases. 1. A method for characterizing a subject's risk profile of developing a future neurologic disease , comprising:obtaining a level of gelsolin in the subject,comparing the level of the gelsolin to a predetermined value, andcharacterizing the subject's risk profile of developing a neurologic disease based upon the level of gelsolin in comparison to the predetermined value, wherein a level of gelsolin at or below the predetermined level is indicative that the subject is at an elevated risk of developing the neurologic disease, and wherein a level of gelsolin at or above the predetermined level is indicative that the subject is not at an elevated risk of developing the neurologic disease.2. The method of claim 1 , wherein the neurologic disease is a demyelinating disease.3. The method of claim 1 , wherein the neurologic disease is multiple sclerosis.4. The method of claim 3 , wherein the multiple sclerosis is acute claim 3 , relapsing claim 3 , remitting claim 3 , stable claim 3 , chronic claim 3 , or probable.5. The method of claim 1 , wherein the neurologic disease is acute disseminated encephalomyelitis claim 1 , transverse myelitis claim 1 , progressive multifocal leukoencephalopathy claim 1 , adrenoleukodystrophy claim 1 , adrenomyeloneuropathy claim 1 , central pontine myelinolysis claim 1 , optic neuritis claim 1 , neuromyelitis optica (Devic's syndrome) claim 1 , Leber's hereditary optic neuropathy claim 1 , tropical spastic paraparesis (HTLV-associated myelopathy) claim 1 , or Guillain-Barré syndrome (also called acute inflammatory demyelinating polyneuropathy claim 1 , acute idiopathic polyradiculoneuritis claim 1 , acute idiopathic polyneuritis claim 1 , French Polio and Landry's ascending paralysis).6. The method of claim 1 , wherein the level of gelsolin is in a ...

Biodegradable Magnetic Nanoparticles and Related Methods

The design of biodegradable magnetic nanoparticles for use in in-vivo biomedical applications. The particles can include Fe in combination with one or more of Mg, Zn, Si, C, N, and P atoms or other particles. The nanoparticles can be degraded in-vivo after usage. The nanoparticles can cease heating upon reaching a predetermined temperature or other value. 1. A composition comprising:a biocompatible and biodegradable nanoparticle including at least one of amorphous alloy, partial-crystalline alloy or crystalline alloy structure; andthe nanoparticle includes an alloy of Fe and at least one of Mg, Zn, or Si.2. The composition as recited in claim 1 , wherein the Fe—Mg claim 1 , or Fe—Zn or Fe—Si amorphous alloy claim 1 , partial-crystalline alloy or crystalline alloy has more than 30 at % Fe.3. The composition as recited in claim 1 , wherein the nanoparticle includes at least one of an amorphous or partial-crystalline alloy or crystalline alloy of Fe with at least one of Mg claim 1 , Zn or Si mixed with elements of at least one of N claim 1 , P claim 1 , S claim 1 , C claim 1 , Ca claim 1 , Ag claim 1 , or Mn.4. The composition as recited in claim 1 , wherein the nanoparticle is a heterostructure having a structure and a matrix claim 1 , the structure includes at least one of FeSi claim 1 , FeZn claim 1 , FeMg claim 1 , FeN claim 1 , FeC or FeP claim 1 , and the matrix includes one or more of Fe claim 1 , Si claim 1 , P claim 1 , N claim 1 , C claim 1 , P claim 1 , Ag. Mn.5. The composition as recited in claim 1 , wherein the nanoparticle includes a heterostructure having at least one of Fe clusters claim 1 , Fe amorphous or Fe alloy clusters claim 1 , or Fe—Mg claim 1 , Zn claim 1 , Si claim 1 , N claim 1 , P claim 1 , C core-shell clusters embedded in Mg claim 1 , Zn claim 1 , Si or a corresponding matrix.6. The composition as recited in claim 1 , wherein the nanoparticle includes at least one of Fe—Mg claim 1 , Zn claim 1 , Si claim 1 , N claim 1 , P claim 1 , or C ...

METHOD AND APPARATUS FOR NONINVASIVE QUANTITATIVE DETECTION OF FIBROSIS IN THE HEART

Embodiments provide a noninvasive quantitative method for detecting extent and/or types of fibrosis in the heart. In embodiments, information pertaining to the extent and/or types of fibrosis may aid in the diagnosis of specific cardiac diseases and heart failure and/or may assist in determining suitable treatment options. Embodiments provide methods and apparatuses for determining the extent of fibrosis in viable and nonviable myocardium, which may then be correlated to heart disease and failure. Thus, in an embodiment, a method of screening individuals for the purpose of heart disease or heart failure prevention may be provided using the detection methodology described herein. 1. A method of detecting fibrosis in heart tissue , comprising:selecting a sample of viable or nonviable heart tissue;contacting the sample with an extracellular contrast agent;obtaining with a magnetic resonance imaging device one or more measurements of the contrast uptake of the sample to determine an extent of expansion of extracellular volume in the sample as an indicator of diffuse interstitial and/or replacement fibrosis, wherein obtaining one or more images using magnetic resonance imaging comprises obtaining a plurality of measurements in blood and in the sample, both before and after contact with one or more contrast agents to determine the tissue sample partition coefficient for the extracellular contrast agent.2. The method of claim 1 , wherein contacting the sample with an extracellular contrast agent comprises contacting the sample with a Gadolinium-containing contrast agent.3. The method of claim 1 , wherein contacting the sample with an extracellular contrast agent comprises contacting the sample with gadodiamide.4. The method of claim 1 , wherein contacting the sample with an extracellular contrast agent comprises contacting the sample with an extracellular collagen-binding contrast agent.5. The method of claim 1 , wherein contacting the sample with an extracellular contrast ...

Biocompatible Agent for Dispersing Nanoparticles into an Aqueous Medium Using Mussel Adhesive Protein-Mimetic Polymer

Provided are a mussel adhesive protein-mimetic dispersion stabilizing agent to disperse nanoparticles in an aqueous medium, a colloidal solution including nanoparticles dispersed and stabilized by the dispersion stabilizing agent, and a contrast agent including the colloidal solution. More particularly, the mussel adhesive protein-mimetic dispersion stabilizer is a polyethyleneimine-graft-(poly-ethyleneglycol;polyDOPA) PEI-graft-(PEG;PDOPA). The graft polymer is formed of two parts. One is polyethyleneglycol grafted with a polyethyleneime which has an affinity to an aqueous medium, and the other is polyDOPA which has an affinity to the surface of nanoparticles. Because of those characteristics, the stabilizer shows a stable dispersion of nano particles in the aqueous medium.

DEEP BRAIN STIMULATION OF MEMORY CIRCUITS IN ALZHEIMER'S DISEASE

Methods and apparatus for screening patients prior to deep brain stimulation to treat cognitive function are provided. One or more patient parameters are processed to produce results. A comparison of the results to a threshold indicates the applicability of the deep brain stimulation therapy. 1. A method for screening patients prior to deep brain stimulation therapy to treat cognitive function , said method comprising:measuring at least one patient parameter to generate at least a first result;comparing the first result to a first threshold;identifying the patient as a candidate for deep brain stimulation therapy based on said comparison of the first result to the first threshold.2. The method of wherein the cognitive function treated comprises a memory function.3. The method of wherein the patient has been diagnosed with a disease or disorder selected from the group consisting of: probable Alzheimer's disease; a genetic form of Alzheimer's disease; mild cognitive impairment; hippocampal damage such as hippocampal damage due to Alzheimer's disease claim 1 , anoxia claim 1 , epilepsy or depression; and combinations thereof.4. The method of wherein the diagnosis was performed within the prior two years.5. The method of wherein the patient comprises a patient between forty and eighty years of age.6. The method of wherein the patient has been diagnosed as an Apo E4 allele carrier.7. The method of wherein the patient has reduced integrity of white matter tracts innervating limbic structures such as the formix as determined by fractional anisotropy maps using diffusion tensor imaging.8. The method of wherein the deep brain stimulation therapy achieves at least one of: treats memory impairment; improves memory function; treats cognitive function loss; reverses synaptic loss; improves cognitive function; reduces degradation of cognitive function; promotes neurogenesis in the hippocampus of the patient's brain; drives neurotrophin expression; regulates one or more biomarkers ...

Opacity technology

A catheter device comprising a chamber containing an opacity enhancing substance is disclosed. The opacity enhancing substance is in a dried or semi-dried form within the chamber of the device. Release of a liquid into the chamber suspends the substance and forms an opacity enhancing solution that is released into the lumen of the device in order to enhance the opacity of the device for imaging.

TREATMENT OF COGNITIVE IMPAIRMENT IN A SUBJECT WITH A NEUROLOGICAL AUTOIMMUNE DISEASE

Described herein are methods for the treatment of cognitive impairment in a subject with a neurological autoimmune disease and methods for determining whether a subject who has a central nervous system autoimmune disease is likely to acquire a cognitive impairment. 1. A method of treating cognitive impairment in a subject who has a central nervous system autoimmune disease , the method comprising administering to the subject an inhibitor of glutamate carboxypeptidase II (GCPII).2. The method of claim 1 , wherein the central nervous system autoimmune disease is multiple sclerosis.3. The method of claim 1 , wherein the brain of the subject or a region of the brain of the subject has a reduced concentration of N-acetylaspartylglutamate (NAAG).4. The method of claim 3 , wherein the concentration of NAAG in the brain of the subject is less than 84% of the mean NAAG concentration of the brain of a healthy subject or the concentration of NAAG in a region of the brain of the subject less than 3.1 mM in the hippocampus or less than 1.9 mM in the frontal white matter.5. The method of claim 1 , wherein the inhibitor of GCPII is an acid linked to a zinc binding group or a NAAG peptide analog.6. The method of claim 5 , wherein the inhibitor of GCPII is 2-(phosphonomethyl) pentanedioic acid (2-PMPA) or 2-(3-mercaptopropyl)pentanedioic acid (2-MPPA).7. The method of claim 1 , wherein the subject has been diagnosed with a cognitive impairment.8. The method of claim 1 , wherein the cognitive impairment is diagnosed using the Brief Repeatable Battery (BRB) claim 1 , the Minimal Assessment of Cognitive Function in MS (MACFIMS) battery or the Symbol Digit Modalities Test (SDMT).9. The method of claim 3 , wherein the method further comprises the step of determining the concentration of NAAG in the brain of the subject or the concentration of NAAG in a region of the brain of the subject.10. The method of claim 9 , wherein the concentration of NAAG in the brain of the subject or the ...

Perylenequinone derivatives and uses thereof

The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.

METHODS FOR EVALUATING BRAIN-WIDE PARAVASCULAR PATHWAY FOR WASTE CLEARANCE FUNCTION AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS BASED THEREON

Methods are provided for measuring glio-vascular pathway (“glymphatic system”) function in the brain of a mammal which include performing imaging of the brain and measuring cerebrospinal fluid-interstitial fluid (CSF-ISF) exchange in the brain. The methods can be used to track the exchange between CSF and ISF compartments. An imaging agent is optionally administered intrathecally. The imaging agent can be a negative or positive (paramagnetic) contrast agent and dynamic or contrast-enhanced magnetic resonance imaging (MRI) of the brain can be performed. The imaging agent can be a positron-emitting radionuclide tracer and positron emission tomography (PET) can be performed. Methods for treating diseases or disorders of the mammalian brain are also provided, in which the methods increase or decrease glymphatic clearance. 177-. (canceled)80. The method of wherein the waste product is soluble amyloid β(Aβ) claim 79 , tau claim 79 , or alpha synuclein.82. A method for decreasing or impeding clearance of a therapeutic or modulatory agent from the brain interstitium of a mammal comprising:decreasing or impeding glymphatic clearance, wherein decreasing or impeding glymphatic clearance comprises administering an agent to the mammal that decreases or impedes glymphatic clearance, wherein the agent is bumetanide, small interfering RNA (siRNA) directed against AQP4, an agonist of AVP (vasopressin), an agonist of atrial natriuretic peptide (ANP), an agonist of Angiotensin II, an agonist of AT2R receptors, or an agonist of AT1 receptors.83. The method of wherein decreasing or impeding glymphatic clearance comprises blocking or erecting a barrier to fluid flow through the central nervous system interstitium of the mammal.85. The method of claim 84 , wherein the neurodegenerative disease is Parkinson's disease (PD) claim 84 , Alzheimer's disease (AD) claim 84 , Alzheimer's disease with Lewy bodies claim 84 , Lewy body dementia claim 84 , mixed dementia claim 84 , vascular dementia ...

METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS

A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject. 1. A method for treating a subject with multiple sclerosis , comprisingadministering to the subject a therapeutically effective amount of an IL-2 receptor antagonist in the absence of treatment with beta interferon,wherein the subject has failed to respond to previous treatment with beta interferon,thereby ameliorating a sign or symptom of multiple sclerosis and treating the subject.2. The method of claim 1 , wherein the IL-2 receptor antagonist is administered intravenously.3. The method of claim 2 , wherein the IL-2 antagonist comprises an antibody that specifically binds the IL-2 receptor.4. The method of claim 3 , wherein the antibody is a humanized monoclonal antibody.5. The method of claim 4 , wherein the antibody specifically binds p55.6. The method of claim 4 , wherein the antibody is administered at a dose of about 1 to about 3 milligrams per kilogram intravenously.7. The method of claim 4 , wherein the antibody is administered at a dose of about 1 per kilogram to about 2 milligrams per kilogram intravenously.8. The method of claim 3 , wherein the antibody is administered biweekly.9. The method of claim 1 , wherein treatment of the subject results in a decreased number of contrast enhancing-lesions as evaluated by Magnetic Resonance Imaging.10. The method of claim 1 , wherein the treatment with beta interferon comprises treatment with interferon-beta 1 a.11. The method of claim 1 , wherein the treatment with beta interferon comprises treatment with interferon-beta 1b.12. The method of claim 1 , wherein the subject has relapsing-remitting multiple sclerosis.13. The method of claim 1 , ...

Tumorspecific PET/MR(T1), PET/MR(T2) and PET/CT contrast agent

New types of nanoparticle-based dual-modality positron emission tomography/magnetic resonance imaging (PET/MRI) and positron emission tomography/computed tomography (PET/CT) tumorspecific contrast agents have been developed. The base of the new type contrast agents is biopolymer-based nanoparticle with PET, MRI and CT active ligands. The nanoparticle contains at least one polyanion and polycation, which form nanoparticles via ion-ion interaction. The self-assembled polyelectrolytes can transport gold nanoparticles as CT contrast agents, or SPION or Gd(III) ions as MRI active ligands, and are labeled using a complexing agent with gallium as PET radiopharmacon. Furthermore, these dual modality PET/MRI and PET/CT contrast agents are labeled with targeting moieties to realize the tumorspecificity. 1. A targeting PET/MRI or PET/CT tumorspecific nanoparticulate contrast composition comprising (i) at least two , preferably water-soluble , biocompatible and biodegradable nanoparticle polyelectrolyte biopolymers; (ii) a targeting molecule conjugated a polyanion biopolymer; (iii) a complexing agent conjugated to a polycation biopolymer , (iv) an MR or CT active ligand complexed to the nanoparticles , and (v) a radionuclide , preferably gallium complexed to the nanoparticles.2. The targeting contrast composition as claimed in claim 1 , wherein the MR or CT active ligand is a paramagnetic ion claim 1 , preferably a lanthanide or a transition metal ion claim 1 , more preferably a gadolinium- claim 1 , a manganese- or a chromium-ion claim 1 , most preferably a gadolinium ion as T1 MR active ion claim 1 , a superparamagnetic iron oxide nanoparticle (SPION) as T2 MR active ligand claim 1 , or a gold nanoparticle as CT contrast ligand.3. The targeting contrast composition as claimed in claim 1 , whereina) the gadolinium ions are complexed to the nanoparticles via complexing agents conjugated to a polycation biopolymer; orb) the SPION or gold nanoparticles are formed in presence of a ...

Method for the Treatment of Multiple Sclerosis

A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject. 1. A method for treating a subject with multiple sclerosis , comprisingadministering to the subject a therapeutically effective amount of an IL-2 receptor antagonist in the absence of treatment with beta interferon,wherein the subject has failed to respond to previous treatment with beta interferon,thereby ameliorating a sign or symptom of multiple sclerosis and treating the subject.2. The method of claim 1 , wherein the IL-2 receptor antagonist is administered intravenously.3. The method of claim 2 , wherein the IL-2 antagonist comprises an antibody that specifically binds the IL-2 receptor.4. The method of claim 3 , wherein the antibody is a humanized monoclonal antibody.5. The method of claim 4 , wherein the antibody specifically binds p55.6. The method of claim 4 , wherein the antibody is administered at a dose of about 1 to about 3 milligrams per kilogram intravenously.7. The method of claim 4 , wherein the antibody is administered at a dose of about 1 per kilogram to about 2 milligrams per kilogram intravenously.8. The method of claim 3 , wherein the antibody is administered biweekly.9. The method of claim 1 , wherein treatment of the subject results in a decreased number of contrast enhancing-lesions as evaluated by Magnetic Resonance Imaging.10. The method of claim 1 , wherein the treatment with beta interferon comprises treatment with interferon-beta 1a.11. The method of claim 1 , wherein the treatment with beta interferon comprises treatment with interferon-beta 1b.12. The method of claim 1 , wherein the subject has relapsing-remitting multiple sclerosis.13. The method of claim 1 , ...

TETANUS TOXOID AND CCL3 IMPROVE DC VACCINES

Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4 T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy. 119-. (canceled)20. A method of immunizing a human , comprising: administering a first acellular immunogen to the human; and administering a second immunogen to the human , whereby administration of the first immunogen increases migration of the second immunogen to vaccine draining lymph nodes (VDLNs) , and wherein the first and second administrations are separated by 1 hour to 4 weeks.21. The method of claim 20 , wherein the first acellular immunogen is selected from the group consisting of tetanus toxoid claim 20 , diphtheria toxoid claim 20 , tetanus and diphtheria toxoids claim 20 , pneumococcal conjugate vaccine (PCV) claim 20 , and haemophilus b conjugate vaccine.22. The method of claim 20 , wherein the second immunogen comprises a cytomegalovirus (CMV) antigen or an RNA encoding a CMV antigen.23. The method of claim 22 , wherein the CMV antigen is pp65.24. The method of claim 20 , wherein the second immunogen comprises dendritic cells pulsed with a CMV integument protein pp65 RNA.25. The method of claim 20 , wherein the method further comprises administering chemokine (C-C motif) ligand 3 (CCL3) to the human.26. The method of claim 20 , wherein the first immunogen ...

Cobalt-based mri contrast agent and imaging system

Novel, non-toxic cobalt-based contrast and imaging agents for use in enhanced medical imaging modalities and processes are described, as well the manufacture of markers containing such contrast agents is described, and uses for such imaging markers and contrast agents in a variety of therapeutic applications and devices.

QUANTIFYING MASS EFFECT DEFORMATION WITH STRUCTURAL RADIOMICS IN BRAIN TUMOR PATIENTS

Methods and apparatus quantify mass effect deformation in diagnostic images of patients demonstrating glioblastoma multiforme (GBM). One example apparatus includes an image acquisition circuit that acquires an image of a region of tissue demonstrating GBM pathology, a delineation circuit that segments a tumor region from the image, a pre-processing circuit that generates a pre-processed image by pre-processing the segmented image, a registration circuit that registers the pre-processed image with a template image of a healthy brain, a deformation quantification circuit that computes a set of differences between a position of a brain sub-structure represented in the registered image relative to the position of the brain sub-structure represented in the template image. Embodiments may include a classification circuit that classifies the region of tissue as a long or short-term survivor based, at least in part, on the set of differences. 1. A non-transitory computer-readable storage device storing computer-executable instructions that when executed by a computer control the computer to perform a method , the method comprising:accessing a diagnostic image of a region of tissue in a patient demonstrating glioblastoma multiforme (GBM) pathology;generating a segmented diagnostic image by segmenting a tumor region from the diagnostic image;generating a pre-processed diagnostic image by pre-processing the segmented diagnostic image;generating a registered diagnostic image by registering the pre-processed diagnostic image with a healthy template; andcomputing a quantified difference between the pre-processed diagnostic image and the healthy template.2. The non-transitory computer-readable storage device of claim 1 , where the diagnostic image is a gadolinium (Gd) contrast T1w claim 1 , T2w claim 1 , or fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) image.3. The non-transitory computer-readable storage device of claim 1 , where segmenting the ...

NMR spectroscopy and MRI methods and systems

A method of performing Nuclear Magnetic Resonance (NMR) spectroscopy or Magnetic Resonance Imaging (MRI). The methods may include: a) generating a compound comprising a first nuclear species (I), a second nuclear species (I), a third nuclear species (S), a heteronuclear coupling asymmetry (|J−J|) and a nuclear singlet state spin order localized on Iand I; b) transferring the nuclear singlet state spin order into heteronuclear magnetization localized on S by applying a single, non-recursive pulse sequence at a low magnetic field in the strong coupling regime of protons; and c) performing NMR spectroscopy or MRI with the compound comprising heteronuclear magnetization localized on S. The |J−J| may be non-zero. The pulse sequence may include a plurality of sequential radio frequency pulses separated by independent evolution interval. The pulse sequence may be capable of transferring at least about 75% of the nuclear singlet state spin order into heteronuclear magnetization localized on S at any |J−J| when the independent evolution intervals are optimized. 2. The method of claim 1 , wherein generating a compound comprises hyperpolarizing the compound by parahydrogen induced polarization (PHIP).3. The method of claim 1 , wherein the compound has a Hamiltonian of{'br': None, 'i': H=', 'π[J', 'I', '·I', 'J', 'I', 'S', '+J', 'I', 'S, 'sub': 12', '1', '2', '1S', '1z', 'z', '2S', '2z', 'z, '2()+].'}4. The method of claim 1 , wherein the pulse sequence comprises a first portion and a second portion claim 1 , wherein the first portion converts the nuclear singlet state spin order localized on Iand Iinto a pure state which is coupled to S claim 1 , and wherein the second portion converts the pure state which is coupled to S into longitudinal net magnetization on S.5. The method of claim 1 , wherein the pulse sequence comprises the following sequential steps:{'sub': '1', 'a) waiting a time tafter generating the compound;'}{'sub': 1', '2, 'b) applying a 180(+x) pulse on Iand I ...

METHODS OF TREATMENT OF CANCER

The present invention provides a method of treating cancer with a proteasome inhibitor. The invention provides a method for treating a patient with a proteasome inhibitor based on measurements of tumor features using biomedical imaging techniques. The invention also provides a method of treating a patient with cancer based on levels of GLUT4, as measured by a biomedical imaging technique. The invention also provides a method of treating a cancer patient with a proteasome inhibitor based on the effect of the treatment on tumor features measured by a biomedical imaging technique. 2. The method of claim 1 , wherein the biomedical imaging technique is selected from the group consisting of tomography claim 1 , magnetic resonance claim 1 , and ultrasound.3. The method of claim 2 , wherein the tomography is positron emission tomography (PET).4. The method of claim 3 , wherein the PET measures a quantity of the standard uptake value (SUV) and wherein the SUV is a quantity of an imaging agent selected from the group consisting of F-fluorodeoxyglucose (FDG) claim 3 , F-fluoro-L-thymidine (FLT) claim 3 , C-acetate and C-choline.5. (canceled)6. The method of claim 1 , wherein the cancer comprises a solid tumor.7. (canceled)8. The method of claim 1 , wherein the cancer comprises a hematological tumor.9. (canceled)10. The method of claim 1 , wherein the repeat measurement is between 1 and 6 cycles of treatment with the compound.11. The method of claim 1 , wherein the repeat measurement is during the first cycle of treatment with the compound.1214.-. (canceled)15. The method of claim 2 , wherein the magnetic resonance is magnetic resonance spectroscopy (MRS) and wherein the MRS measures a quantity of a molecule selected from the group consisting of glucose claim 2 , lactate claim 2 , acetate and choline.1617.-. (canceled)18. The method of claim 6 , wherein the solid tumor has wild type KRAS or has wild type EGFR.19. (canceled)20. The method of claim 6 , wherein the solid tumor has ...

Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI)

The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity. 1. A method for detecting patent foramen ovale in a patient comprising:administering a T1-reducing contrast agent and a T2-reducing contrast agent to the patient; andimaging the patient's heart;wherein diffusion of the T2 reducing contrast agent from the right atrium to the left atrium is indicative of patent foramen ovale.2. The method of claim 1 , wherein the particle size of the T2-reducing contrast agent is larger than the particle size of the T1-reducing contrast agent3. The method of claim 1 , wherein the T1-reducing contrast agent and the T2-reducing contrast agent are administered to the patient as a single composition.4. The method of claim 1 , wherein the T1-reducing agent and the T2-reducing contrast agent are administered to the patient as two separate compositions.5. The method of claim 1 , wherein administering T1-reducing contrast agent and the T2-reducing contrast agent are completed simultaneously.6. The method of claim 1 , wherein imaging the patient's heart comprises imaging via magnetic resonance imaging.7. The method of claim 1 , wherein imaging the patient's heart is performed within about 10 minutes of administration of the T1-reducing contrast agent and the T2-reducing contrast agent.8. The method of claim 1 , wherein the first T1-reducing contrast agent comprises a gadolinium compound.9. The method of claim 8 , wherein the gadolinium compound is selected from gadopentetate dimeglumine (Gd-DTPA) claim 8 , gadoterate meglumine claim 8 , gadoversetamide claim 8 , gadoteridol claim 8 , gadodiamide claim 8 , gadobenate dimeglumine claim 8 , gadobutrol claim 8 , gadoxetate disodium claim 8 , gadofosveset trisodium and combinations thereof.10. The method of claim 1 , wherein the T2-reducing contrast agent comprises an iron oxide.11. The method of claim 10 , ...

Calibration of mri systems using pre-defined concentrations of 19f isotopes as reference

A kit for calibrating a magnetic resonance imaging (MRI) system using defined concentration of 19 F isotopes as well as a device for calibrating a MRI system using the kit. Further, a method for calibrating a MRI system employing the kit as well as to an entity comprising a defined concentration of 19 F isotopes to be used in the calibration of a MRI system.

Compositions and Methods for Assessing and Treating Adrenal Diseases and Disorders

The present invention relates to the discovery that mutations in KCNJ5 are associated with adrenal diseases and disorders. The invention includes compositions and methods for the assessment, characterization and treatment of adrenal diseases and disorders, based upon the presence or absence of a KCNJ5 mutation that is associated with an adrenal disease or disorder. 1. An isolated KCNJ5 polypeptide having an amino acid sequence comprising at least one mutation in or near the KCNJ5 selectivity filter.2. The isolated KCNJ5 polypeptide of claim 1 , wherein the at least one mutation is at amino acid residue position from about 140 to about 180 relative to SEQ ID NO:13.3. The isolated KCNJ5 polypeptide of claim 1 , wherein the at least one mutation is at least one selected from the group consisting of G151X claim 1 , L168X claim 1 , T158X and E145X.4. The isolated KCNJ5 polypeptide of claim 1 , wherein the at least one mutation is at least one selected from the group consisting of G151A claim 1 , L168R claim 1 , T158A and E145Q.5. An isolated KCNJ5 nucleic acid having a nucleotide sequence comprising at least one mutation claim 1 , wherein the nucleic acid having at least one mutation encodes a polypeptide having an amino acid sequence comprising at least one mutation in or near the KCNJ5 selectivity filter.6. The isolated KCNJ5 nucleic acid of claim 5 , wherein the nucleic acid having at least one mutation encodes a polypeptide having an amino acid sequence comprising at least one mutation at an amino acid residue position from about 140 to about 180 relative to SEQ ID NO:13.7. The isolated KCNJ5 nucleic acid of claim 5 , wherein the nucleic acid having at least one mutation encodes a polypeptide having an amino acid sequence comprising at least one mutation selected from the group consisting of G151X claim 5 , L168X claim 5 , T158X and E145X.8. The isolated KCNJ5 nucleic acid of claim 5 , wherein the nucleic acid having at least one mutation encodes a polypeptide having ...

HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES

Systems, methods and related devices used to produce and collect polarized noble gas to inhibit, suppress, detect or filter alkali metal nanoclusters to preserve or increase a polarization level thereof. The systems can include a pre-sat chamber that has an Area Ratio between 20 and 500. 1. A flow-through optical spin exchange hyperpolarized gas production system for producing hyperpolarized gas comprising:a pre-saturation chamber comprising an Area Ratio (AR) of between 20 and 500, wherein the pre-saturation chamber comprises alkali metal therein;a heat source in communication with the pre-saturation chamber configured to heat the pre-saturation chamber to between 140 Celsius and 300 Celsius;a flow-through optical pumping cell in fluid communication with the pre-saturation chamber;{'sup': '129', 'a gas mixture comprising Xe gas in the optical pumping cell; and'}a heat source in communication with the optical pumping cell, wherein the heat source is configured to heat the optical pumping cell to a temperature that is less than the pre-saturation chamber,{'sup': 129', '129, 'wherein the system hyperpolarizes the Xe gas in the optical pumping cell and provides at least one bolus amount of the hyperpolarized Xe gas for inhalation delivery to a patient.'}2. The system of claim 1 , further comprising an accumulator in fluid communication with the optical pumping and located downstream of the optical pumping cell claim 1 , wherein the accumulator collects the at least one bolus amount of the hyperpolarized Xe gas.3. The system of claim 2 , further comprising a bag that is releasably coupled to the accumulator and that holds the at least one bolus amount of the hyperpolarized gas for inhalation delivery to the patient.4. The system of claim 3 , wherein the at least one bolus amount of hyperpolarized Xe gas in the bag has sufficient hyperpolarization level when dispensed to the patient in an MRI scanner to obtain MR spectroscopy data and/or MRI image data of at least one of ...

COMPOSITIONS AND DEVICES TO ADMINISTER PHARMACEUTICAL COMPOSITIONS NASALLY

Devices and methods for nasal administration of a pharmaceutical composition. In certain embodiments, the devices comprises a reservoir, a conduit in fluid communication with the reservoir, and an anatomic positioning device configured to position the conduit in a nasal cavity of a user. Particular embodiments include an actuator configured to transfer the pharmaceutical composition from the reservoir to the conduit and emit the pharmaceutical composition from the conduit. 1. An apparatus for nasal administration of a pharmaceutical composition , the apparatus comprising:a reservoir;a conduit in fluid communication with the reservoir;an actuator configured to transfer a pharmaceutical composition from the reservoir to the conduit and emit the pharmaceutical composition from the conduit; andan anatomic positioning device configured to position the conduit in a nasal cavity of a user.2. The apparatus of wherein the anatomic positioning device is modeled after anatomic features of an individual user.3. The apparatus of wherein the anatomic positioning device is modeled after a computerized tomography (CT) scan of an individual user.4. The apparatus of wherein the anatomic positioning device is modeled after a magnetic resonance imaging (MRI) scan of a nasal cavity of an individual user.5. The apparatus of wherein the anatomic positioning device comprises: the adjustable member can be adjusted to control a depth at which the conduit is inserted into the nasal cavity; and', 'the adjustable member can be adjusted to control an angle at which the conduit is inserted into the nasal cavity., 'an adjustable member coupled to the conduit, wherein6. The apparatus of wherein the conduit is threaded and the adjustable member is threadably coupled to the conduit.7. The apparatus of wherein the anatomic positioning device further comprises:a dial mechanism for controlling the depth and the angle at which the conduit is inserted into the nasal cavity.8. The apparatus of wherein ...

Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies

The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.

System and Method For Evaluation of Subjects Using Magnetic Resonance Imaging and Oxygen-17

A system and method for evaluating subjects using MRI and a contrast agent that overcomes the low sensitivity nature of previous detection methods is provided by using a 3D golden-angle-based radial sampling approach. In one configuration, direct detection of metabolic HO generated from mitochondrial respiration may be imaged. Radial encoding allows for the use of ultra-short echo-time to compensate for signal loss due to the short Trelaxation time of O and other contrast agents. In addition, the golden-ratio-based sampling scheme has the flexibility of enabling various undersampling schemes and retrospective selection of temporal resolution for dynamic imaging. A 3D radial sampling scheme may also give rise to additional SNR gain by further shortening the echo-time. 1. A method for O imaging using a magnetic resonance imaging (MRI) system comprising:{'sup': '17', 'a) administering O to a subject;'}{'sup': '17', 'b) acquiring MR data for a region of interest containing the O within the subject using the MRI system;'} i) segmenting k-space into at least one region;', 'ii) determining a number of spokes for the at least one k-space region based upon a radial sampling pattern;', 'iii) determining a spoke spacing for the number of spokes in the radial sampling pattern using a golden-ratio; and, 'c) applying a k-space filter to the MR data to create filtered MR data by{'sup': '17', 'd) reconstructing an MR image of the O within the subject using the filtered MR data.'}2. The method of wherein determining a number of spokes includes using a Fibonacci sequence to uniformly distribute the spokes in the at least one k-space region.3. The method of wherein the number of spokes is determined for at least two k-space regions and the Fibonacci sequence determines a different number of spokes for a second k-space region than the number of spokes in a first k-space region.4. The method of wherein the number of spokes in the at least one k-space region fulfills a Nyquist sampling ...

HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES

Systems, methods and related devices used to produce and collect polarized noble gas to inhibit, suppress, detect or filter alkali metal nanoclusters to preserve or increase a polarization level thereof. The systems can include a pre-sat chamber that has an Area Ratio between 20 and 500. 1. A flow-through optical spin exchange hyperpolarized gas production system for producing hyperpolarized gas comprising:a pre-saturation chamber comprising an Area Ratio (AR) of between 20 and 500, wherein the pre-saturation chamber comprises alkali metal therein;a heat source in communication with the pre-saturation chamber configured to heat the pre-saturation chamber to between 140 Celsius and 300 Celsius;a flow-through optical pumping cell in fluid communication with the pre-saturation chamber; anda heat source in communication with the optical pumping cell, wherein the heat source is configured to heat the optical pumping cell to a temperature that is less than the pre-saturation chamber.2. The system of claim 1 , wherein the pre-saturation chamber has an AR that is between 20 and 200 claim 1 , optionally about 100.3. The system of claim 1 , wherein a new and/or previously unused pre-saturation chamber comprises rubidium (Rb) in an amount between 0.5 and 5 grams.4. The system of claim 1 , wherein the pre-saturation chamber is replaceably and interchangeably detachable from the hyperpolarized gas production system for another pre-saturation chamber having a common size and shape and pre-filled with the alkali metal to thereby allow for a plurality of pre-saturation chambers to be used with the same optical pumping cell over production cycles.5. The system of claim 1 , further comprising a pressurized flow manifold that resides upstream of the optical pumping cell and maintains a gas flow path into the optical pumping cell at a defined pressure claim 1 , wherein the pre-saturation chamber is a detachable pre-saturation chamber that is interchangeably claim 1 , sealably attached ...

IMAGING OF CREATINE KINASE ENZYME EXPRESSION IN CANCEROUS TISSUES

The present technology is directed to apparatuses, machines and methods for determining the level of expression of creatine kinase enzyme in cancerous tissues, as well as for determining malignancy and providing a cancer prognosis. 1. A method of visually determining the level of expression of creatine kinase enzyme in a cancerous tissue , the method comprising the steps of:(a) exposing the cancerous tissue to phosphocreatine; and(b) irradiating the cancer tissue with a radio frequency (RF) pulse.2. The method of claim 1 , wherein the cancerous tissue is exposed to the phosphocreatine by any of the following methods: intravenous injection of the phosphocreatine into the body of a patient claim 1 , or injection of the phosphocreatine directly into the site of the cancerous tissue.3. The method of claim 1 , wherein the cancerous tissue is a tumor.4. The method of claim 1 , wherein the visual indication is created with magnetic resonance imaging.5. A method of determining the malignancy of a cancerous tissue claim 1 , the method comprising the steps of:(a) injecting phosphocreatine into the cancerous tissue; and(b) measuring the extent or rate of conversion of phosphocreatine into creatine in the cancerous tissue over a given time period;wherein the extent or rate of conversion of phosphocreatine into creatine in the cancerous tissue over the given time period is indicative of the malignancy of the cancerous tissue.6. A method of providing a cancer prognosis claim 1 , the method comprising the steps of:(a) injecting phosphocreatine intravenously into tissue known or thought to be cancerous; and(b) measuring the extent or rate of conversion of phosphocreatine into creatine in the cancerous tissue over a given time period.7. An apparatus for monitoring the extent or rate of conversion of phosphocreatine to creatine in the body of a patient; the apparatus comprising:(a) a radio source capable of providing a radio frequency (RF) pulse to the body of the patient; and(b) a ...

Contrast agents based on long-lived nuclear singlet states and related methods

Methods are described for preparing magnetic resonance imaging (MRI) and/or magnetic resonance spectroscopy contrast agents where the contrast agents are prepared from precursor molecules having at least four non-zero-spin nuclei that form two pairs of chemically equivalent or effectively equivalent nuclei, e.g., diphenylacetylene or diethyl oxalate. The precursor molecule is hyperpolarized and a sequence of one or more radiofrequency pulses is applied to transfer spin state population between the first and second pair of nuclei, thereby providing a non-equilibrium single state nuclear spin population. To detect the contrast agent, another sequence of one or more radiofrequency pulses is applied to transfer singlet order to polarization. No transformation of the molecular structure of the contrast agent is necessary for detection. Also described are methods of imaging targets using the contrast agents.

Contrast Agents for Magnetic Resonance Imaging

Ascorbate or a pharmaceutically acceptable salt thereof is described for use in carrying out a method, or for the preparation of a medicament for carrying out a method, of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject. The method is carried out by parenterally administering ascorbate or a pharmaceutically acceptable salt thereof to the subject in an MRI image-enhancing amount; and then generating, by MRI of the subject, an image of the body or body region. The ascorbate or pharmaceutically acceptable salt thereof enhances the MRI image. 1. A method of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject , comprising:parenterally administering a composition comprising ascorbate or a pharmaceutically acceptable salt thereof to said subject in an MRI image-enhancing amount, wherein said composition comprises meglumine, a sugar or a sugar alcohol; and thengenerating, by MRI of the subject, an image of said body or body region,whereby said composition enhances the MRI image.2. The method of claim 1 , wherein said body region is a head claim 1 , neck claim 1 , thorax claim 1 , abdomen claim 1 , pelvis claim 1 , limb(s) claim 1 , muscle claim 1 , fat claim 1 , or bone.3luteum. The method of claim 1 , wherein said organ comprises an adrenal gland claim 1 , pituitary claim 1 , thymus claim 1 , corpus claim 1 , retina claim 1 , brain claim 1 , spleen claim 1 , lung claim 1 , testicle claim 1 , lymph nodes claim 1 , liver claim 1 , thyroid claim 1 , small intestinal mucosa claim 1 , leukocytes claim 1 , pancreas claim 1 , kidney claim 1 , or salivary gland tissue.4. The method of claim 1 , wherein said body region is a brain.5. The method of claim 1 , wherein said body region is a heart.6. The method of claim 1 , wherein said ascorbate or pharmaceutically salt thereof is administered in an amount of from 0.02 grams per kilogram ...

Using Heavy Water as a Contrast Agent for Hydrogen Magnetic Resonance Imaging

A method of using an imaging contrast agent is provided for hydrogen magnetic resonance imaging (H MRI). The agent uses replacement and chemical exchange of hydrogen (H) and deuterium (D) on obtaining MRI images for comparison. An isotonic physiologic saline solution with deuterium oxide (DO) is made. The solution is intravenously injected to obtain the intensity alterations on MRI images. The injected DO is perfused into tissue and replace the original water. Exchanges between H and D occur and a solution of hydrogen deuterium oxide (HDO) is obtained. After such mechanisms, MRI images are compared for differences. Thus, a novel, non-radioactive, non-toxic and non-invasive MRI agent is provided for people who are allergic to general imaging agents. 1. A method of providing a fast , non-radioactive , non-toxic and non-invasive imaging contrast agent for use in perfusion MRI , comprising:{'sub': '2', 'administering heavy water (deuterium oxide, DO) as a contrast agent of hydrogen magnetic resonance imaging (MRI); and'}{'sup': '1', 'sub': '2', 'indirectly detecting the deuterium (D) by measuring the difference of signal intensities of hydrogen (H) before and after administration of DO.'}2. The method according to claim 1 , wherein said imaging contrast agent is produced by the method comprising:{'sub': '2', '(a) preparing isotonic physiologic saline by sodium chloride and DO;'}{'sub': '2', '(b) putting said solution of DO into a living object through intravenous injection;'}(c) scanning said living object through MRI; and(d) obtaining changes of brightness and contrast in images of said living object.4. The method of claim 2 , wherein the DO is injected into said living object at an amount of 0.1˜20% of weight of said living object.5. The method of claim 1 , wherein the sensitivity of indirect detection of DO is up to 100 times higher than the direct detection. This application claims priority to U.S. patent application Ser. No. 13/555,377, filed Jul. 23, 2012, a non- ...

MAGNETIC APPARATUS

An apparatus includes a magnetic apparatus that defines an actuation volume that is large enough to accommodate a sample, the magnetic apparatus including a magnet that is configured to create a magnetic field having a magnitude B in the sample when supplied with a DC current; at least one biological construct within the sample, the biological construct configured to change its status in response to a change in a property; and at least one magnetocaloric actuator coupled with the biological construct. A change in a characteristic in the actuation volume causes the property of the magnetocaloric actuator to change, which causes a change in the status of the biological construct. 1. An apparatus comprising:a magnetic apparatus that defines an actuation volume that is large enough to accommodate a sample, the magnetic apparatus including a magnet that is configured to create a magnetic field having a magnitude B in the sample when supplied with a DC current;at least one biological construct within the sample, the biological construct configured to change its status in response to a change in a property; andat least one magnetocaloric actuator coupled with the biological construct;wherein a change in a characteristic in the actuation volume causes the property of the magnetocaloric actuator to change, which causes a change in the status of the biological construct.2. The apparatus of claim 1 , wherein the sample is a region of a live human body and the magnetocaloric property changes while the temperature in the live human body region is at a human body temperature.3. The apparatus of claim 1 , wherein the change caused to the property of the magnetocaloric actuator occurs without causing a change in status of materials within the sample other than the at least one biological construct.4. The apparatus of claim 1 , further comprising an energy supply connected to the magnet claim 1 , wherein the magnet includes electrically conductive wire coils through which current ...

RECEPTOR IMAGING SYSTEMS AND RELATED METHODS

A method includes administering to a subject (i) a pharmacological agent that binds to receptors in a subject, and (ii) a radiotracer to alter a functional state and occupancy of the receptors in the subject. The method also includes acquiring imaging data of brain tissue in the subject comprising the receptors. The imaging data include positron emission tomography (PET) imaging data and functional magnetic resonance (fMR) imaging data. The method further includes calculating (i) a dynamic response of the functional state to the pharmacological agent and the radiotracer based on the fMR imaging data, and (ii) a dynamic response of the receptor occupancy to the pharmacological agent and the radiotracer based on the PET imaging data. 1. A method comprising:administering to a subject (i) a pharmacological agent that binds to receptors in a subject, and (ii) a radiotracer to alter a functional state and occupancy of the receptors in the subject;acquiring imaging data of brain tissue in the subject comprising the receptors, the imaging data comprising positron emission tomography (PET) imaging data and functional magnetic resonance (fMR) imaging data; andcalculating (i) a dynamic response of the functional state to the pharmacological agent and the radiotracer based on the fMR imaging data, and (ii) a dynamic response of the receptor occupancy to the pharmacological agent and the radiotracer based on the PET imaging data.2. The method of claim 1 , wherein the pharmacological agent and the radiotracer are administered to the subject substantially simultaneously claim 1 , within 5-10 minutes of each other claim 1 , or within 2-3 hours of each other.3. The method of claim 1 , further comprising administering an iron oxide contrast agent before acquiring the imaging data.4. The method of claim 1 , wherein the pharmacological agent or the radiotracer is administered to the subject parenterally.5. The method of claim 1 , wherein the receptor occupancy corresponds to receptor ...

Alkoxyamines for the treatment of cancers

The present invention relates to alkoxyamines of general formula (I), and to compounds of general formula (IIa), (IIb), (IIc), (IId), IIe), (IIf) or (IIg), as such and for the treatment of cancers.

COMPOSITION FOR USE IN IMAGING

The present invention is for a novel composition for imaging using magnetic resonance imaging (MRI), x-rays, and x-ray computed tomography (CT). The composition shows up as an image on all type of MRIs, x-rays and CT scans, and is made of natural ingredients suitable for topical use. The composition is versatile and flexible. The invention is also to a method of using the composition to visualize surfaces and structures that are not visible on scan images, and to more precisely localize internal structures from MRI, x-rays and CT images. 1. A composition comprising vitamin E , a solvent , and fat , wherein the composition is in a form suitable for the topical application to a subject undergoing an imaging procedure , and the composition can be visualized by the imaging procedure.2. The composition of claim 1 , wherein the imaging procedure is selected from the group consisting of magnetic resonance imaging claim 1 , x-ray claim 1 , and x-ray computed tomography imaging.3. The composition of claim 1 , wherein the vitamin E is present in the composition in an amount of about 15 to 60% by volume.4. The composition of claim 1 , wherein the vitamin E is present in the composition in an amount of about 20 to 30% by volume.5. The composition of claim 1 , wherein the vitamin E is present in the composition in an amount of about 15 to 20% by volume.6. The composition of claim 1 , wherein the solvent is selected from the group consisting of water and povidone-iodine.7. The composition of claim 6 , wherein the water is selected from the group consisting of purified claim 6 , distilled claim 6 , double distilled claim 6 , and deionized.8. The composition of claim 1 , wherein the solvent is present in the composition in an amount of about 25 to 75% by volume.9. The composition of claim 1 , wherein the solvent is present in the composition in an amount of about 30 to 45% by volume.10. The composition of claim 1 , wherein the fat is selected from the group consisting of purified ...

Nanoparticle coated with ligand introduced with long hydrophobic chain and method for preparing same

The present invention relates to a nanoparticle having a linker connected to a long alkane or alkene chain, and a method for preparing the nanoparticle. The alkyl chain of C 10-30 introduced with a ligand of the present invention can be coated on a hydrophobic nanoparticle through a noncovalent bond, enabling easy introduction of various ligands to the nanoparticle, and the nanoparticle having various functional groups prepared using the method can be applied to fluorescent detection, MRI, raman spectroscopy, optical detection, PET, SPECT, or gamma image device, and the ligand of the visualization agents can be modified to be used for new vessels detection, cancer cell detection, immunocyte detection, hepatocyte detection, cell death detection, and gene detection.

ROOM TEMPERATURE FERROMAGNETIC GADOLINIUM SILICIDE NANOPARTICLES

A particle usable as Tand Tcontrast agents is provided. The particle is a gadolinium silicide (GdSi) particle that is ferromagnetic at temperatures up to 290 K and is less than 2 μm in diameter. An MRI contrast agent that includes a plurality of gadolinium silicide (GdSi) particles that are less than 1 μm in diameter is also provided. A method for creating gadolinium silicide (GdSi) particles is also provided. The method includes the steps of providing a GdSibulk alloy; grinding the GdSibulk alloy into a powder; and milling the GdSibulk alloy powder for a time of approximately 20 minutes or less. 1. A ferromagnetic material , comprising:{'sub': 5', '4', '5', '4', '5', '4, 'a gadolinium silicide (GdSi) particle, wherein the GdSiparticle is ferromagnetic at temperatures up to 290 K and wherein the GdSiparticle is less than 2 μm in diameter.'}2. The material according to claim 1 , wherein the GdSiparticle remains ferromagnetic at temperatures up to 310 K.3. The material according to claim 1 , wherein the GdSiparticle is less than 1 μm in diameter.4. The material according to claim 1 , wherein the GdSiparticle is less than 500 nm in diameter.5. The material according to claim 1 , wherein the GdSiparticle includes 5 wt % or less GdSi.6. An MRI contrast agent claim 1 , wherein the MRI contrast agent comprises:{'sub': 5', '4', '5', '4, 'a plurality of gadolinium silicide (GdSi) particles, wherein the GdSiparticles are less than 1 μm in diameter.'}7. The MRI contrast agent according to claim 6 , wherein the GdSiparticles are ferromagnetic at temperatures up to 310 K.8. A method for creating gadolinium silicide (GdSi) particles comprising the steps of:{'sub': 5', '4, 'providing a GdSibulk alloy;'}{'sub': 5', '4', '5', '4, 'grinding the GdSibulk alloy into a GdSibulk alloy powder; and'}{'sub': 5', '4, 'milling the GdSibulk alloy powder for a time of approximately 20 minutes or less.'}9. The method of claim 8 , wherein the grinding and milling steps further comprise using an ...

Method for Detection of Characteristics of Organ Fibrosis

The disclosed invention is a method for detecting indications of the presence of liver disease and other fibrotic diseases using a magnetic-resonance based technique for measuring fine tissue and bone textures. Specifically, the invention focuses on adaptations to this prior art to facilitate assessment of the presence and severity of liver disease, lung disease, and other fibrotic disease by measuring spatial wavelengths characteristic of the specific disease process across an areal cross-section through an organ. The results may be presented using a mapping technique. In this way, the resolution of MR is extended further than possible with current MR imaging, so as to be able to measure the fine scale structures and tissue changes that are known to be characteristic of the degenerative processes involved in the development of these diseases. 1. A method of assessing the development of fibrotic structure within an organ of a patient in response to disease of the patient comprising:acquiring spatially-encoded MR echoes along an acquisition axis of a selectively-excited internal volume positioned within a targeted region in a patient while applying a magnetic field gradient;analyzing the spatially-encoded MR echoes along an acquisition axis in the selectively-excited internal volume to yield a spectrum of textural wavelengths in a region of interest along a spatially-encoded axis of the internal volume as a marker of the disease;assessing the development of fibrotic disease from the spectrum of textural wavelengths in the region of interest in the organ in comparison to known spectrums of textural wavelengths in a corresponding region of interest in the organ taken from the same or different patients.2. The method of wherein assessing the conditions or disease comprises analyzing selected ranges of the spectrum of textural wavelengths.3. The method of further comprising using a relative integrated intensity within the selected ranges of structural wavelength for ...

PHARMACEUTICAL COMPOSITIONS OF NEAR IR CLOSED CHAIN, SULFO-CYANINE DYES

Sterile and non-toxic pharmaceutical compositions of near IR, closed chain, sulfo-cyanine dyes and methods for visualizing tissue under illumination with near-infrared radiation are provided. 4. The composition of claim 1 , wherein the composition unit dosage form is 0.05 claim 1 , 0.10 claim 1 , 0.20 claim 1 , 0.30 claim 1 , 0.35 claim 1 , 0.40 claim 1 , 0.45 claim 1 , 0.50 claim 1 , 0.55 claim 1 , 0.60 claim 1 , 0.65 claim 1 , 0.70 claim 1 , 0.75 claim 1 , 0.80 claim 1 , 0.90 claim 1 , 1 claim 1 , 2 claim 1 , 4 claim 1 , 6 claim 1 , or 8 mg/kg.5. The composition of where the composition is adapted for administration to a human patient to obtain visualization of human tissue under illumination with near-infrared radiation wherein the unit dosage form is between 0.05 and 8 mg/kg.6. The composition of where the composition is dry and a single dose form.7. The composition of where the composition is lyophilized in a sterile container.8. The composition of where the composition is contained within a sterile container claim 1 , where the container has a machine detectable identifier which is readable by a medical device.9. The composition of further comprising combination with pharmaceutically acceptable excipients in an oral dosage form.10. The composition of further comprising combination with pharmaceutically acceptable carriers in an injectable dosage form.11. The composition of further comprising combination with pharmaceutically acceptable excipients in a dosage form for direct application to a surgical site.12. The use of a composition of adapted for administration to a patient to obtain visualization of tissue under illumination with near-infrared radiation wherein the unit dosage form is between 0.05 and 8 mg/kg.13. The use of adapted for administration to a human patient to obtain visualization of human tissue under illumination with near-infrared radiation wherein the unit dosage form is between 0.05 and 8 mg/kg.14. A method for visualization of tissue claim ...

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOARTHRITIS

The present invention relates to the field of osteoarthritis. More specifically, the present invention provides compositions and methods useful for treating or preventing osteoarthritis. In one embodiment, a method for treating or preventing osteoarthritis in a patient comprises the step of administering to the patient a therapeutically effective amount of a transforming growth factor beta (TGF-beta) inhibitor. 1. A method for treating or preventing osteoarthritis in a patient comprising the step of administering to the patient a therapeutically effective amount of a transforming growth factor beta (TGF-beta) inhibitor.2. The method of claim 1 , wherein the TGF beta is a member of the TGF-beta superfamily.3. The method of claim 1 , wherein the TGF-beta is TGF-beta 1 claim 1 , TGF-beta 2 claim 1 , TGF-beta 3.4. The method of claim 1 , wherein the TGF-beta is TGF-beta 1.5. The method of claim 1 , wherein the inhibitor is a small molecule claim 1 , an antibody claim 1 , a protein claim 1 , a peptide claim 1 , or a nucleic acid.6. The method of claim 1 , wherein the inhibitor is an antibody.7. The method of claim 1 , wherein the inhibitor inhibits active TGF-beta claim 1 , a TGF-beta receptor claim 1 , a protease responsible for activating a precursor TGF-beta into mature TGF-beta claim 1 , expression of TGF-beta claim 1 , or combinations of the foregoing.8. The method of claim 1 , wherein the inhibitor is administered into the subchondral bone area.9. A method for treating or preventing osteoarthritis osteoarthritis in a patient comprising the step of administering to the patient a therapeutically effective amount of a TGF-beta inhibitor into the subchondral bone area.10. A method for treating or preventing osteoarthritis osteoarthritis in a patient comprising the step of administering to the patient a therapeutically effective amount of a TGF-beta 1 blocking antibody into the subchondral bone area.11. A method for reducing the degeneration of articular cartilage in a ...

SYSTEMS AND METHODS OF DETECTING INTERSTITIAL CYSTITIS

The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity.

Compositions and methods for molecular imaging of oxygen metabolism

Provided are compositions containing an emulsion containing a perfluorinated compound, as well as methods for preparation of the compositions. Also provided are formulations containing a complex of oxygen-17 and the emulsion compositions. Additionally provided are methods for the preparation of the formulations as well as kits containing the formulations. Further provided are methods of use of the formulations in imaging of tissues using a magnetic resonance imaging system.

Exendin-4 Peptide Analogues

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake 2. The compound of claim 1 ,which is a GLP1 and Glucagon receptor agonist.3. The compound of claim 1 , wherein Ris NH.4. The compound of claim 1 , wherein the peptidic compound has a relative activity of at least 0.1% compared to that of natural glucagon at the glucagon receptor.5. The compound of claim 1 , wherein the peptidic compound exhibits a relative activity of at least 0.1% compared to that of GLP-1(7-36) at the GLP-1 receptor.6. The compound of claim 1 , whereinX2 represents an amino acid residue selected from Ser, D-Ser or Aib,X3 represents His,X18 represents an amino acid residue selected from His or Leu,X20 represents an amino acid residue selected from His, Arg, Lys, Gln, or (S)MeLys,X21 represents an amino acid residue selected from Asp or Glu,X28 represents an amino acid residue selected from Lys, Ser or Ala, andX32 represents an amino acid residue selected from Ser or Val.7. The compound of claim 1 , whereinX2 represents an amino acid residue selected from Ser, D-Ser or Aib,X3 represents GlnX18 represents Leu,X20 represents Lys,X21 represents an amino acid residue selected from Asp or Glu,X28 represents Ala, andX32 represents Ser.8. The compound of claim 1 , whereinX2 represents an amino acid residue selected from Ser, D-Ser or Aib,X3 represents an amino acid residue selected from Gln or His,X18 represents an amino acid residue selected from His or Leu,X20 represents Lys,X21 represents an amino acid residue selected from Asp or Glu,X28 represents an amino acid residue selected from Lys, Ser, or Ala, andX32 represents an amino acid residue selected from Ser or Val.9. The compound of claim 1 , whereinX2 represents an amino acid residue selected from Ser, D-Ser or Aib,X3 represents an amino acid residue selected from Gln or His,X18 ...

Nanoparticle Diagnostic and Methods for Treating Disease

The present invention relates to the use of in vivo contrast agents in medical imaging in order to diagnose and treat disease, and to monitor and assess disease progression following treatment with a nanoparticle therapeutic agent comprising an active pharmaceutical agent. The present invention also relates to modulating nanoparticle tumor concentration by modulating the PEG density of the nanoparticles. 1. A method of selecting a subject to be treated with a nanoparticle therapeutic agent (NTA) , the method comprising:(a) administering a contrast agent to the subject;(b) measuring the level of accumulation of the contrast agent at at least one intended site of treatment; and(c) selecting the subject for NTA treatment based on the level of the accumulation of the contrast agent;wherein the intended site of treatment is a tumor.2. The method of claim 1 , wherein the contrast agent and NTA differ from one another based on at least one selected parameter by at least 2 fold.3. The method of claim 2 , wherein the selected parameters are size claim 2 , density claim 2 , or surface charge.4. The method of claim 1 , further comprising comparing the level of accumulation at the intended site of treatment to a reference claim 1 , and treating the subject with the NTA if there is an increase in the level of accumulation compared to the reference.5. The method of claim 4 , wherein the reference is measured in the subject at a reference site and the reference site is plasma claim 4 , bone claim 4 , or muscle.6. The method of claim 1 , wherein the contrast agent comprises a moiety selected from a fluorescent moiety claim 1 , a luminescent moiety claim 1 , a radioactive moiety claim 1 , and a magnetic moiety.7. The method of claim 6 , wherein the contrast agent is ferumoxytol claim 6 , AngioSense® claim 6 , or AngioSPARK®.8. The method of claim 1 , wherein the level of accumulation of the contrast agent is measured with an imaging technique selected from ultrasound claim 1 , X-ray ...

Imaging marker and utilization thereof

As an imaging marker for generating suitable contrasts in images taken through a plurality of medical diagnostic imaging techniques, a liquid containing a transition metal belonging to any of the fifth to seventh periods of the periodic table or a compound thereof in high concentration and/or high density or a composition containing the liquid is provided. Use of the composition easily generates a suitable contrast in any of the plurality of medical diagnostic imaging techniques.

Contrast medium composition and method of bio imagination using the same

The present invention relates to contrast medium composition and a method of bio imagination using the same. The contrast medium composition of the present invention includes a biomolecule, DNA nanostructure, as an active ingredient, is fundamentally non-cytotoxic and non-immunogenic and is not likely to induce safety problems that may be observed in other organic or inorganic contrast medium composition. In addition, the contrast medium composition of the present invention not only facilitates diagnosis of disease through sufficient contrast enhancement effect by showing excellent cellular uptake and intracellular stability and can visualize even SLNs which is difficult to be visualized traditionally, so can judge metastasis of cancer easily and apply lower invasive treatment.

NANOPARTICULATE CONTRAST AGENT

Provided is a nanoparticulate composite with two layers. One of the layers comprises one or more metals, which are a paramagnetic metal, a ferromagnetic metal, or a superparamagnetic metal. This layer also contains one or more suitable dopants. The other layer comprises one or more metals of gadolinium, manganese (II), and iron (III), in the form of an oxide or a fluoride. This layer may contain one or more lanthanide dopants. The nanoparticulate composite may be used as a contrast agent, in particular in magnetic resonance imaging. 115-. (canceled)16. A nanoparticulate composite comprising a first and a second layer ,{'sup': 3+', '3+, 'wherein the first layer comprises one or more metals and one or more dopants, wherein the one or more metals comprise dysprosium as a paramagnetic metal, a ferromagnetic metal, and a superparamagnetic metal, and wherein the first layer comprises an Yb dopant and a Dy dopant,'}wherein the second layer comprises one or more metals selected from the group consisting of gadolinium, manganese (II), and iron (III), the one or more metals being an oxide, a fluoride or a phosphate.17. The nanoparticulate composite of claim 16 , wherein the one or more metals comprised in the first layer are an oxide or a fluoride.18. The nanoparticulate composite of claim 16 , wherein the one or more metals comprised in the first layer comprise one or more of DyO claim 16 , DyF claim 16 , NaDyF claim 16 , LiDyF claim 16 , KDyF.19. The nanoparticulate composite of claim 16 , wherein the amount of Dy dopant is higher than the amount of Yb dopant in the first layer.20. The nanoparticulate composite of claim 16 , wherein the one or more metals comprised in the second layer comprise one or more of GdF claim 16 , GdO claim 16 , MnO claim 16 , MnO claim 16 , GdPO claim 16 , LiMnF claim 16 , NaMnF claim 16 , KMnF claim 16 , LiGdF claim 16 , NaGdF claim 16 , KGdF claim 16 , NaY(Yb)F:Gd claim 16 , NaY(Yb)F:Mn claim 16 , LiY(Yb)F:Gd claim 16 , KY(Yb)F:Gd claim 16 , LaF ...

Malignant tumor target peptide

The present invention provides a peptide comprising the amino acid sequence of any of the formulas (I-(III) below: (I) an amino acid sequence of (X1)[D]P[D](X2)[D] wherein X1 is W or F, X2 is S or T, and each amino acid symbol immediately followed by symbol [D] is a D form of the amino acid, (II) an amino acid sequence of P[D]T[D](X) n F[D] wherein (X) n is any amino acid in the number of n selected independently of each other, n is an integer of 0-4, and the symbol [D] is as defined above, (III) an amino acid sequence that is a Retro-inverso of the amino acid sequence of any of the aforementioned (I) and the aforementioned (II); and a conjugate containing the peptide and a functional part.

MULTIPURPOSE MEDICAL IMAGE INDICATOR AND METHOD FOR MANUFACTURING THE SAME

The present disclosure concerns a medical image indicator. More particularly, it concerns the multipurpose medical image indicator including more than one of fluorophores and MRI contrast agent/CT contrast agent and method for manufacturing same. Responding to a demand for non-invasive and effective way of marking lesions, the present disclosure provides a method for manufacturing the multipurpose medical image indicator including a provision of rubber material fluid composition; a mixing of the rubber material fluid composition and fluorophores; and a transfiguring and drying of the mixture and the multipurpose medical image indicator manufactured according to the method. Further, the present disclosure provides a ligation device for endoscope including the multipurpose medical image indicator. 1. A method for manufacturing multipurpose medical image indicator , comprising ,provision of rubber material fluid composition;mixing of the rubber material fluid composition and fluorophores; andtransfiguring and drying of the mixture to form a fluorescent rubber band.2. A method for manufacturing multipurpose medical image indicator of claim 1 ,wherein the rubber material fluid composition includes a rubber material, a crosslinking agent, an accelerator, an active agent, and an anti-aging agent.3. A method for manufacturing multipurpose medical image indicator of claim 2 ,wherein in the rubber material fluid composition,the crosslinking agent is a sulfur crosslinking agent;the accelerator is an accelerator including more than one of sulfide, sulfenamide, and carbamate;the active agent is an active agent including more than one of zinc oxide or stearate; andthe anti-aging agent is the anti-aging agent including more than one of amines, imidazole, and quinone.4. A method for manufacturing multipurpose medical image indicator of claim 3 ,wherein the rubber material 100 weight of the rubber material fluid composition comprises,sulfur cross linker 1.0 to 2.0 weight, carbamate ...

Estrogen therapy for brain gray matter atrophy and associated disability

Provided are methods for slowing, halting, and reversing gray matter atrophy and progression of disability in certain neurodegenerative diseases, including multiple sclerosis, using estrogen, alone or in combination with another agent.

Imaging Brown Adipose Tissue with Curcumin Derivatives

Methods and compositions for imaging Brown adipose tissue (BAT) in living mammals, e.g., humans. 3. The method of claim 1 , wherein detecting the imaging agent comprises detecting fluorescence emission from the imaging agent; detecting gamma rays; detecting nuclear magnetic resonance (NMR); or detecting ultrasonic emissions.4. The method of claim 1 , wherein the BAT imaging agent is selected from the group consisting of CRANAD-2 claim 1 , CRANAD-3 claim 1 , CRANAD-29 claim 1 , and CRANAD-43;5. The method of claim 1 , wherein detecting the imaging agent comprises:setting a region of interest (ROI); andobtaining an image of the region of interest in the mammal.6. The method of claim 5 , further comprising processing the image to provide a measure of BAT levels or activity in the mammal.7. The method of claim 2 , comprising one or both of:administering CRANAD-2 to the mammal, and processing the image to provide a measure of BAT activity, and/oradministering CRANAD-29 to the mammal, and processing the image to provide a measure of BAT levels.8. The method of claim 5 , wherein the ROI covers one or more of the cervical claim 5 , supraclavicular claim 5 , and superior mediastinal areas of the mammal.9. The method of claim 1 , comprising:obtaining an image by detecting fluorescence emission from the imaging agent, or detecting ultrasonic emissions; andprocessing the image to provide information regarding BAT levels or activity in the mammal.11. The method of claim 1 , wherein the imaging agent comprises a positron-emitting radionuclide claim 1 , and the method comprises:obtaining an image by detecting gamma radiation from the BAT imaging agent; andprocessing the image to provide information regarding BAT levels or activity in the mammal.12. The method of claim 1 , wherein the imaging agent comprises C claim 1 , O claim 1 , or F atom claim 1 , and the method comprises:obtaining an image by detecting BAT using an imaging modality suitable for detecting the spin of those ...

Contrast Agents for Magnetic Resonance Imaging

Ascorbate or a pharmaceutically acceptable salt thereof is described for use in carrying out a method, or for the preparation of a medicament for carrying out a method, of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject. The method is carried out by parenterally administering ascorbate or a pharmaceutically acceptable salt thereof to the subject in an MRI image-enhancing amount; and then generating, by MRI of the subject, an image of the body or body region. The ascorbate or pharmaceutically acceptable salt thereof enhances the MRI image. 1. A method of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject , comprising:parenterally administering a composition comprising ascorbate or a pharmaceutically acceptable salt thereof to said subject in an MRI image-enhancing amount, wherein said composition comprises a spin-spin exchange catalyst; and thengenerating, by MRI of the subject, an image of said body or body region,whereby said composition enhances the MRI image.2. The method of claim 1 , wherein said body region is a head claim 1 , neck claim 1 , thorax claim 1 , abdomen claim 1 , pelvis claim 1 , limb(s) claim 1 , muscle claim 1 , fat claim 1 , or bone.3. The method of claim 1 , wherein said organ comprises an adrenal gland claim 1 , pituitary claim 1 , thymus claim 1 , corpus luteum claim 1 , retina claim 1 , brain claim 1 , spleen claim 1 , lung claim 1 , testicle claim 1 , lymph nodes claim 1 , liver claim 1 , thyroid claim 1 , small intestinal mucosa claim 1 , leukocytes claim 1 , pancreas claim 1 , kidney claim 1 , or salivary gland tissue.4. The method of claim 1 , wherein said body region is a brain.5. The method of claim 1 , wherein said body region is a heart.6. The method of claim 1 , wherein said ascorbate or pharmaceutically salt thereof is administered in an amount of from 0.02 grams per kilogram subject body ...

SYSTEMS AND METHODS OF DETECTING INTERSTITIAL CYSTITIS

The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity. 2. The method of claim 1 , wherein the particle size of the T2-reducing contrast agent is larger than the particle size of the T1-reducing contrast agent3. The method of claim 1 , wherein the T1-reducing agent claim 1 , the T2-reducing agent claim 1 , or a combination thereof further comprises an aqueous solvent.4. The method of claim 1 , wherein the T1-reducing contrast agent and the T2-reducing contrast agent are administered to the patient as a single composition; wherein the single composition comprises the T1-reducing contrast agent and the T2-reducing contrast agent.5. The method of wherein the single composition further comprises an aqueous solvent.6. The method of claim 1 , wherein the T1-reducing agent and the T2-reducing contrast agent are administered to the patient as two separate compositions; wherein a first composition comprises the T1-reducing. contrast agent; and wherein a second composition comprises the T2-reducing contrast agent7. The method of claim 6 , wherein the two separate compositions each further comprise an aqueous solvent.8. The method of claim 1 , wherein administering T1-reducing contrast agent and the T2-reducing contrast agent are completed simultaneously.9. The method of claim 1 , wherein imaging the patient comprises imaging via magnetic resonance imaging.10. The method of claim 1 , wherein imaging the patient is performed within about 10 minutes of administration of the T1-reducing contrast agent and the T2-reducing contrast agent.11. The method of claim 1 , wherein the first T1-reducing contrast agent comprises a gadolinium compound.12. The method of claim 11 , wherein the gadolinium compound is selected from gadopentetate dimeglumine (Gd-DTPA) claim 11 , gadoterate meglumine claim 11 , gadoversetamide claim 11 , gadoteridol claim 11 , ...

Magnetic Resonance Imaging (MRI) Based Quantitative Kidney Perfusion Analysis

Example apparatus and methods provide improved spatial and temporal resolution over conventional magnetic resonance renography (MRR). Example apparatus and methods reconstruct under-sampled three-dimensional (3D) data associated with nuclear magnetic resonance (NMR) signals acquired from a kidney. The data is reconstructed using a 3D through-time non-Cartesian generalized auto-calibrating partially parallel acquisitions (GRAPPA) approach. Example apparatus and methods produce a quantized value for a contrast agent concentration in the kidney from a signal intensity in the data based, at least in part, on a two compartment model of the kidney. The two compartment model includes a plasma compartment and a tubular compartment. The quantized value describes a perfusion parameter for the kidney or a filtration parameter for the kidney. Greater precision is achieved for estimates of the perfusion parameter or filtration parameter as a result of the quantization performed on data acquired with greater spatial resolution and temporal resolution. 1. A method , comprising:controlling a magnetic resonance imaging (MRI) apparatus to acquire a series of three-dimensional (3D) data sets, where a member of the series of 3D data sets is associated with a portion of a kidney, and where the series of 3D data sets are acquired during a free-breathing dynamic contrast enhanced (DCE) MRI procedure that includes presenting a contrast agent to the kidney;controlling the MRI apparatus to reconstruct the series of 3D data sets into a corresponding series of 3D images using a 3D through-time non-Cartesian generalized auto-calibrating partially parallel acquisitions (GRAPPA) approach; andproducing a quantified value for a renal perfusion parameter for the kidney as a function of a signal intensity associated with the concentration of contrast agent in the kidney as displayed in one or more members of the series of 3D images and as a function of a two compartment model of a kidney, where the ...

SUPERPARAMAGNETIC NANOPARTICLES AS A CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING (MRI) OF MAGNETIC SUSCEPTIBILITY (T2*)

The invention relates to the use of biocompatible superparamagnetic nanoparticles comprising an inorganic core and a coating including an electrically charged polymer, and having low tissue and vascular adhesion, for use as contrast agents in magnetic resonance imaging (MRI). The aforementioned nanoparticles have novel pharmacokinetic and relaxability T2* properties, with high potential for use in in vivo tissue imaging and tumour perfusion strategies based on parameter T2*. 119-. (canceled)20. A contrast agent for T2*-weighted magnetic resonance imaging (MRI) comprising one or more nanoparticles having a core less than 15 nm in diameter and surface net electrical charge comprising: 1) an inorganic core and 2) a water-soluble polymer coating , which does not accumulate in the liver or spleen , having serum relaxivity values r2* greater than 90mM , characterised n that:{'sub': 3', '4, 'i) the inorganic core is composed of magnetite FeO—; and'}ii) the water-soluble polymer coating is polyacrylic acid.21. A process for performing T2*-weighted magnetic resonance imaging (MRI) of biological tissues in vivo comprising the step of administering the contrast agent defined in in animals and humans.22. The process according to claim 21 , wherein MRI is for perfusion measurements in healthy tissues and in pathologies affecting vascular disorders claim 21 , tissular ischaemia claim 21 , neurodegeneration claim 21 , inflammation claim 21 , oedema or cancer. The present invention relates to the field of magnetic resonance, especially the use of superparamagnetic nanoparticles as contrast agents for non-invasive imaging of tissue or tumor perfusion. Its applications may also extend to other fields of biomedicine or diagnostic imaging.Magnetic Resonance imaging constitutes a very useful tool for non-invasively monitoring tissue perfusion and tumors (U. Haberkom and A. Altmann, Current Gene Therapy 2001, 1 (2), 163; T. Ichikawa et al., Neoplasia 2002, 4 (6), 523; D. C. Sullivan and ...

DEVICES AND METHODS FOR PARAHYDROGEN INDUCED POLARIZATION

The present invention teaches devices and methods for hyperpolarization by parahydrogen induced polarization. The invention teaches several significant improvements over previous designs, including a heating block, an enhanced solenoid component, and pinch valves and tubing that provide a sterile environment for the sample. All of these advancements can be accomplished while keeping costs to produce the device relatively low. 1. A device for parahydrogen induced polarization , comprising:(1) a reactor, comprising a first reactor inlet, a second reactor inlet, and a reactor outlet;(2) a precursor receiving tube, comprising a first precursor receiving tube end and a second precursor receiving tube end, wherein the first precursor receiving tube end is mechanically connected to the first reactor inlet;(3) a parahydrogen receiving tube, comprising a first parahydrogen receiving tube end and a second parahydrogen receiving tube end, wherein the first parahydrogen receiving tube end is mechanically connected to the second reactor inlet;(4) an outlet tube, comprising a first outlet tube end and a second outlet tube end, wherein the first outlet tube end is mechanically connected to the reactor outlet;(5) a radio frequency (RF) coil enveloping the reactor along the vertical axis thereof;(6) a solenoid coil enveloping the RF coil along the vertical axis thereof; and(7) a metal heating block, comprising a longitudinal axis comprising a plurality of grooves situated perpendicular thereto, wherein each of the plurality of grooves are configured to accommodate a section of the precursor receiving tube, and wherein the section of the precursor receiving tube is wrapped around the grooves of the metal heating block.2. The device of claim 1 , further comprising one or more pinch valves claim 1 , wherein the pinch valves are configured to compress one or more segments of one or more of the precursor receiving tube claim 1 , the parahydrogen receiving tube and the outlet tube.3. A ...

TREATMENT OF NEUROLOGICAL DISORDERS

This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution. 127-. (canceled)28. A system useful in determining an effective amount of a therapeutic composition comprising an iRNA agent for treating a central nervous system disorder in a mammal comprising: a catheter configured to be implanted in the brain of the mammal , and a tracing composition comprising the iRNA agent labeled with a detectable label and wherein the iRNA agent comprises an antisense sequence that is substantially complementary to a target RNA in the brain such that that the iRNA agent is capable of decreasing the expression of the target RNA in the brain , and wherein the labeled iRNA agent comprises a detectable label , wherein the detectable label does not adversely affect the effectiveness of the labeled iRNA agent to decrease expression of the target RNA as compared to the iRNA agent without the label , and wherein the detectable label does not adversely effect the distribution of the labeled iRNA agent in the brain as compared to the labeled iRNA agent without the label.29. The system of wherein the label is carbon-14 claim 28 , the central nervous system disorder is Huntington's disease claim 28 , and the target RNA is a huntingtin RNA.30. The ...

COLOR TUNABLE MULTIFUNCTIONAL NANOPHOSPHOR, SYNTHESIS METHOD THEREOF, AND POLYMER COMPOSITE INCLUDING THE NANOPHOSPHOR

A nanophosphor in accordance with one exemplary embodiment of the present disclosure includes a fluoride-based nanoparticle co-doped with Ceand one selected from a group consisting of Tb, Euand a combination thereof. The nanophosphor may be excited by a single wavelength of ultraviolet rays to emit various colors of green, yellow, orange, red and the like, and exhibit high photostability without photoblinking. The nanophosphor may be utilized as a bio imaging contrast agent, a transparent display device, an anti-counterfeit code and the like. 1. A nanophosphor comprising a fluoride-based nanoparticle expressed by the following chemical formula 1 and co-doped with Ceand one selected from a group consisting of Tb , Euand a combination thereof ,{'br': None, 'sub': 1-w-x-y-z', 'w', '4', 'x', 'y', 'z, 'sup': 3+', '3+', '3+, 'NaYGdF:Ce,Tb,EU\u2003\u2003[Chemical formula 1]'}where≦x≦denotes a real number in the range of 0.1≦x≦0.5,≦y≦denotes a real number in the range of 0≦y≦0.4,≦z≦denotes a real number in the range of 0≦z≦0.3, w denotes a real number in the range of 0≦w≦0.9, and 0 Подробнее

CHEMICAL EXCHANGE SATURATION TRANSFER ANGIOGRAPHY

The invention provides a novel approach for effective ex vivo and in vivo imaging of blood and establishes the feasibility of blood as an effective agent for CEST to generate sufficient CEST contrast relative to surrounding tissue. 1. A method for imaging blood of a mammal , including human , in vivo comprising imaging the mammal using a CEST-based magnetic resonance imaging procedure wherein blood of the subject serves as the CEST contrast agent.2. The method of claim 1 , wherein the method is non-invasive.3. The method of claim 1 , wherein the method images an artery claim 1 , vein or heart chamber of the mammal.4. The method of claim 1 , wherein one or more exogenous CEST contrast agents are used for further enhancement of imaging contrast.5. The method of claim 1 , wherein no exogenous CEST contrast agent is used.6. A method for performing angiography of a mammal claim 1 , including human claim 1 , comprising performing CEST imaging with blood serving as the endogenous CEST contrast agent.7. The method of claim 6 , wherein the angiography is the imaging of an artery of the subject.8. The method of claim 7 , wherein the artery is selected from femoral artery claim 7 , carotid artery claim 7 , aorta claim 7 , pulmonary artery claim 7 , brachialis artery claim 7 , hepatic artery claim 7 , and iliac artery.9. The method of claim 6 , wherein the angiography is the imaging of a vein of the mammal.10. The method of claim 9 , wherein the vein is selected from great saphenous vein claim 9 , pulmonary veins claim 9 , hepatic portal vein and hypophyseal portal system claim 9 , and Thebesian veins.11. The method of claim 6 , wherein the angiography is the imaging of one or more heart chambers of the mammal.12. The method of claim 6 , wherein the angiography is the imaging of one or more parts of the brain of the mammal.13. The method of claim 6 , wherein the angiography is performed without any exogenous CEST contrast agent.14. A method for diagnosing a mammal claim 6 , ...

Ascorbate Formulations and Methods of Use as Contrast Agents

A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L. 2. The composition of claim 1 , wherein said spin-spin exchange catalyst is meglumine.3. The composition of claim 1 , wherein said composition further comprises carbonate and/or phosphate.4. The composition of claim 1 , wherein said spin-spin exchange catalyst is a reducing sugar.5. The composition of claim 1 , wherein said spin-spin exchange catalyst is a non-reducing sugar.6. The composition of claim 1 , wherein said composition has an osmolarity of 200-1200 mOsm/L.7. The composition of claim 1 , wherein said composition has a pH of from 6.5 to 7.5.8. The composition of claim 1 , wherein said composition further comprises a stability agent.9. The composition of claim 1 , wherein said composition is provided in unit dosage form.10. The composition of claim 9 , wherein said unit dosage form comprises from 10 to 100 grams of ascorbate.11. The composition of claim 1 , wherein said composition comprises meglumine ascorbate and sodium ascorbate in a molar or millimolar (mM) ratio of from 10:90 claim 1 , 20:80 claim 1 , 30:70 claim 1 , or 40:60 claim 1 , up to 90:10 claim 1 , 80:20 claim 1 , 70:30 claim 1 , or 60:40 (meglumine ascorbate:sodium ascorbate).12. A powder composition comprising:ascorbate;meglumine, or a combination-of sodium and meglumine;optionally, carbonate and/or phosphate; andoptionally, a reducing or non-reducing sugar,said composition suitable for use, upon addition of a sterile liquid carrier, in enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject.13. The composition of claim 12 , wherein said composition comprises carbonate and/or phosphate.14. The composition of claim 12 , wherein said composition comprises a reducing sugar.15. The composition of ...

Oncolytic Vaccinia Virus Combination Cancer Therapy

Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.

HYPERPOLARIZATION OF AMINO ACID RESIDUES FOR PRODUCING HYPERPOLARIZED PEPTIDES

The invention relates to the field of Magnetic Resonance Imaging (MRI). More particularly, the invention relates to hyperpolarized peptides for use in MRI. 1. A hyperpolarized peptide , comprising: at least one hyperpolarized alanine residue and one or more other amino acid residues.2. The hyperpolarized peptide of claim 1 , wherein the one or more other amino acid residues is any natural amino acid or unnatural amino acid.3. The hyperpolarized peptide of claim 1 , wherein the one or more other amino acid residues is any natural amino acid.4. The hyperpolarized peptide of claim 1 , wherein the at least one hyperpolarized alanine residue comprises a non-hydrogen non-zero nuclear spin nucleus.5. The hyperpolarized peptide of claim 4 , wherein the non-hydrogen non-zero nuclear spin nucleus is C.6. The hyperpolarized peptide of claim 5 , wherein the C is present at a level according to its natural isotopic abundance.7. The hyperpolarized peptide of claim 5 , wherein the C is present at a level greater than its natural isotopic abundance.8. The hyperpolarized peptide of claim 1 , wherein one or more hydrogen atoms is replaced with a deuterium atom.9. A method for preparing a hyperpolarized peptide claim 1 , comprising:providing a reagent peptide comprising at least one dehydroalanine residue and one or more other amino acid residues;contacting the reagent peptide with molecular hydrogen enriched with para-hydrogen and a hydrogenation catalyst under conditions effective to form a para-hydrogenated peptide; andsubjecting the para-hydrogenated peptide to a polarization transfer sequence to obtain the hyperpolarized peptide.10. The method of claim 9 , wherein the one or more other amino acid residues is any natural amino acid or unnatural amino acid.11. A method of imaging a subject claim 9 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering a hyperpolarized peptide of to the subject; and'}imaging the subject after administering the hyperpolarized ...

A method of purifying metal oxide particles and uses thereof

A method of purifying a plurality of metal oxide particles produced from a synthesis process is disclosed. The method comprises the step of washing a plurality of metal oxide particles in a first solvent composition comprising of at least one aliphatic ether, and at least one flocculant. In one embodiment, the plurality of metal oxide particles are iron oxide particles produced from a thermal decomposition synthesis process between an iron-oleate complex and oleic acid in 1-octadecene, wherein the first solvent composition comprises a 1:1 (vol/vol) ratio of an aliphatic ether in the form of diethyl ether and a flocculant in the form of methanol. The washed iron oxide particles are further washed in a second solvent composition comprising a 1:1 (vol/vol) ratio of hexane and ethanol, and then finally dispersed in hexane. The resulting iron oxide particles find use as a contrast agent for magnetic resonance imaging (MRI) or as magnetic particles in magnetic separation, magnetism-directed targeting or magnetism-induced heating.

Tetanus Toxoid and CCL3 Improve DC Vaccines

Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4 T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy. 1. A pharmaceutical composition comprising a combination of a first acellular immunogen and a second immunogen , said combination selected from the group consisting of:(a) tetanus toxoid and chemokine CCL3;(b) diphtheria toxoid and chemokine CCL3;(c) tetanus toxoid and a tumor specific or tumor associated antigen;(d) tetanus toxoid and an antigen of an infectious agent;(e) diphtheria toxoid and a tumor specific or tumor associated antigen;(f) diphtheria toxoid and an antigen of an infectious agent;(g) chemokine CCL3 and a tumor specific antigen; and(h) chemokine CCL3 and an antigen of an infectious agent.2. A kit comprising a first acellular immunogen and second immunogen for administration to a human ,{'i': 'haemophilus', 'wherein the first acellular immunogen is selected from the group consisting of tetanus toxoid, diphtheria toxoid, tetanus-diphtheria toxoids, pneumococcal conjugate vaccine (PCV), and b conjugate vaccine, and'}wherein the second immunogen is selected from the group consisting of a tumor-associated, a tumor-specific antigen, an antigen of an infectious agent, a dendritic cell vaccine, an antigen-pulsed dendritic cell vaccine, and dendritic cells pulsed ...

METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS

A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject. 1. A method for treating a subject with multiple sclerosis , comprisingadministering to the subject a therapeutically effective amount of an IL-2 receptor antagonist in the absence of treatment with beta interferon,wherein the subject has failed to respond to previous treatment with beta interferon,thereby ameliorating a sign or symptom of multiple sclerosis and treating the subject.2. The method of claim 1 , wherein the IL-2 receptor antagonist is administered intravenously.3. The method of claim 2 , wherein the IL-2 antagonist comprises an antibody that specifically binds the IL-2 receptor.4. The method of claim 3 , wherein the antibody is a humanized monoclonal antibody.5. The method of claim 4 , wherein the antibody specifically binds p55.6. The method of claim 4 , wherein the antibody is administered at a dose of about 1 to about 3 milligrams per kilogram intravenously.7. The method of claim 4 , wherein the antibody is administered at a dose of about 1 per kilogram to about 2 milligrams per kilogram intravenously.8. The method of claim 3 , wherein the antibody is administered biweekly.9. The method of claim 1 , wherein treatment of the subject results in a decreased number of contrast enhancing-lesions as evaluated by Magnetic Resonance Imaging.10. The method of claim 1 , wherein the treatment with beta interferon comprises treatment with interferon-beta 1a.11. The method of claim 1 , wherein the treatment with beta interferon comprises treatment with interferon-beta 1b.12. The method of claim 1 , wherein the subject has relapsing-remitting multiple sclerosis.13. The method of claim 1 , ...

NANOPARTICLE DIAGNOSTIC AND METHODS FOR TREATING DISEASE

The present invention relates to the use of in vivo contrast agents in medical imaging in order to diagnose and treat disease, and to monitor and assess disease progression following treatment with a nanoparticle therapeutic agent comprising an active pharmaceutical agent. The present invention also relates to modulating nanoparticle tumor concentration by modulating the PEG density of the nanoparticles. 1. A method of selecting a subject to be treated with a nanoparticle therapeutic agent (NTA) , the method comprising:(a) administering a contrast agent to the subject;(b) measuring the level of accumulation of the contrast agent at at least one intended site of treatment; and(c) selecting the subject for NTA treatment based on the level of the accumulation of the contrast agent;wherein the intended site of treatment is a tumor.2. The method of claim 1 , wherein the contrast agent and NTA differ from one another based on at least one selected parameter by at least 2 fold.3. The method of claim 2 , wherein the selected parameters are size claim 2 , density claim 2 , or surface charge.4. The method of claim 1 , further comprising comparing the level of accumulation at the intended site of treatment to a reference claim 1 , and treating the subject with the NTA if there is an increase in the level of accumulation compared to the reference.5. The method of claim 4 , wherein the reference is measured in the subject at a reference site and the reference site is plasma claim 4 , bone claim 4 , or muscle.6. The method of claim 1 , wherein the contrast agent comprises a moiety selected from a fluorescent moiety claim 1 , a luminescent moiety claim 1 , a radioactive moiety claim 1 , and a magnetic moiety.7. The method of claim 6 , wherein the contrast agent is ferumoxytol claim 6 , AngioSense® claim 6 , or AngioSPARK®.8. The method of claim 1 , wherein the level of accumulation of the contrast agent is measured with an imaging technique selected from ultrasound claim 1 , X-ray ...

Metal Complexes with Bisphophonate or Pyrophosphate Useful as Imaging Agents

Provided herein are magnetic resonance imaging (MRI) contrast agents comprising a compound having a structure represented by: Y—X—Z, wherein, X is: Fe(III) or Mn(II), and Y and Z are each independently selected from pyrophosphate and bisphosphonate (e.g., 1-hydroxybisphosphonate), or a pharmaceutically acceptable hydrate and/or salt thereof. Methods of use of the MRI contrast agent are also provided. 1. A magnetic resonance imaging (MRI) contrast agent comprising a compound having a structure represented by:{'br': None, 'Y—X—Z'}wherein,X is Fe(III) and Y and Z are each independently selected from the group consisting of pyrophosphate and bisphosphonate;or a pharmaceutically acceptable hydrate and/or salt thereof.2. The MRI contrast agent of claim 1 , wherein the contrast agent has a molecular weight of less than 2 claim 1 ,000 daltons.3. The MRI contrast agent of claim 1 , wherein the contrast agent has a molecular weight of less than 800 daltons.4. The MRI contrast agent of claim 1 , wherein the compound is octahedral.5. The MRI contrast agent of claim 1 , wherein the compound is a monohydrate or a dihydrate.6. The MRI contrast agent of claim 1 , wherein the compound is a salt comprising from 1 to 3 cations.7. The MRI contrast agent of claim 6 , wherein the cations are selected from sodium and meglumine.8. The MRI contrast agent of claim 1 , wherein said MRI contrast agent comprises at least one alkaline earth metal selected from calcium and magnesium.9. The MRI contrast agent of claim 6 , wherein said MRI contrast agent comprises sodium.10. The MRI contrast agent of claim 1 , wherein said compound is Fe(III):(PO):(HO) claim 1 , or a pharmaceutically acceptable salt thereof.12. The MRI contrast agent of claim 1 , wherein said compound is coupled to one or more therapeutic agents.13. The MRI contrast agent of claim 12 , wherein said one or more therapeutic agents are covalently coupled to Y and/or Z.14. A composition comprising the MRI contrast agent of in a ...

METHOD OF USING THE NOVEL POLYMER GEL FOR MAGNETIC RESONANCE IMAGING (MRI) VALIDATION

Novel normoxic N-(Hydroxymethyl) acrylamide (NHMAGAT) polymer gel dosimeters for MRI scanning are introduced for radiotherapy planning system. The composition of the NHMAGAT polymer gel and method of making the NHMAGAT polymer gel dosimeter are disclosed. The dosimeters are irradiated with Varian Rapid Arc linear systems at different absorbed doses. The results show that the percent depth dose and 2D plan dose distribution of NHMAGAT polymer gel dosimeters are in a good agreement with the ionization chamber measurements and CT planned dose distribution, respectively. 1. A method , comprising:exposing a specific polymer gel made up of specific components and stored in a specific container to a specific radiation level; andcalculating using a specific equation (equation 1 and 2) to determine a percent depth during a radiotherapy treatment planning using Magnetic Resonance Imaging (MRI) for a patient.2. The method of claim 1 , wherein the specific polymer gel is a normoxic N-(Hydroxymethyl) acrylamide (NHMAGAT) polymer gel dosimeter made up of specific components.3. The method of claim 2 , wherein the specific components are 1-12% w/w % N-(Hydroxymethyl) acrylamide (NHMA) monomer claim 2 , 1-4% N claim 2 , N -methylene-bis-acrylamide (BIS) cross-linker claim 2 , 2-5 g w/w % gelatin (Type A claim 2 , bloom 300) claim 2 , 0-0.1 mM hydroquinone (HQ) claim 2 , 1-50 mM tetrakis (hydroxymethyl) phosphonium chloride (THPC) and an ultra-pure de-ionized water.4. The method of claim 3 , wherein the specific components are 8 w/w % NHMA monomer claim 3 , 3 w/w % BIS cross-linker claim 3 , 3 w/w % gelatin claim 3 , 0.02 mM HQ claim 3 , 5 mM THPC and the ultra-pure de-ionized water.5. The method of claim 1 , wherein the specific container is at least one of a tube claim 1 , bottle and container.6. The method of claim 1 , wherein the specific radiation level is at least one of a 2 claim 1 , 4 claim 1 , 6 claim 1 , 8 and 10 Gy.7. The method of claim 6 , wherein the specific radiation ...

METHOD AND IMAGE PROCESSOR FOR EVALUATING A CONTRAST AGENT-ENHANCED MAGNETIC RESONANCE SLICE IMAGE OF A HEART

In a method and processor for evaluating a contrast agent-enhanced two-dimensional magnetic resonance slice image of a heart of a patient in order to determine picture elements revealing contrast agent deposits in the myocardium, an endocardium contour in the magnetic resonance slice image, taking into consideration deposition information describing picture elements potentially revealing contrast agent deposits and determined by image analysis on the basis of a shape assumption for the heart structure that is to be examined, in particular the left ventricle, such that picture elements potentially revealing contrast agent deposits are avoided as much as possible as a contour component. An epicardium contour enclosing the endocardium contour is then determined. Picture elements are marked that indicate contrast agent enhancement in the myocardium lying between the epicardium contour and the endocardium contour as contrast agent deposit. 1. A method for evaluating a contrast agent-enhanced two-dimensional magnetic resonance slice image of a heart of a patient in order to determine picture elements in said slice image revealing contrast agent deposits in the myocardium of the heart , said method comprising:providing a computer with a contrast agent-enhanced two-dimensional magnetic resonance slice image of a heart, said slice image being comprised of picture elements;in said computer, determining an endocardium contour of the endocardium of the heart in the magnetic resonance slice image, using deposition information describing picture elements that are candidates for revealing contrast agent deposits, by executing an image analysis based on an assumption, provided to the computer, of a shape for a structure of the heart in the slice image and, in said image analysis, avoiding picture elements as components of said endocardium contour that are said candidates for revealing contrast agent deposits;in said computer, determining an epicardium contour that encloses the ...

NON-INVASIVE DETECTION OF DISEASE PROGRESSION AND THERAPEUTIC EFFICACY FOR MUSCULAR DYSTROPHIES AND DISEASES

Provided herein are non-invasive in vivo imaging methods to evaluate efficacy of a therapeutic intervention for neuromuscular diseases by determining the level and/or localization of a detectable marker that is influenced by another protein which is a target of the therapeutic intervention. Non-invasive imaging methods disclosed herein can involve in vivo molecular imaging such as PET or SPECT, and/or morphological imaging such as MRI or CT. 1. A method of evaluating efficacy of a therapeutic intervention in a subject suffering from a neuromuscular disease , the method comprising:determining level and/or localization of a detectable marker comprising performing in vivo molecular imaging on the subject after the subject undergoes the therapeutic intervention;wherein the level and/or localization of the detectable marker is modulated by a therapeutic target of the therapeutic intervention.2. The method of claim 1 , further comprising performing morphological imaging on the subject.3. (canceled)4. The methods of claim 1 , further comprising performing in vivo molecular imaging on the subject before the subject undergoes the therapeutic intervention.58-. (canceled)9. The method of claim 1 , wherein the therapeutic target is a cytosolic protein claim 1 , a membrane-bound protein claim 1 , a glycoprotein or a matrix-anchoring protein.10. (canceled)11. The method of claim 1 , wherein the neuromuscular disease is one of the following: muscular dystrophy claim 1 , spinal muscular atrophy claim 1 , inflammatory myopathy claim 1 , disease of peripheral nerve claim 1 , disease of neuromuscular junction claim 1 , metabolic disease of muscle claim 1 , central core disease claim 1 , hyperthyroid myopathy claim 1 , myotonia congenita claim 1 , myotubular myopathy claim 1 , nemaline myopathy claim 1 , paramyotonia congenita claim 1 , periodic paralysis-hypokalemic-hyperkalemic myopathy claim 1 , motor neuron disease claim 1 , frailty syndrome or a condition associated with loss of ...

Using Heavy Water as a Contrast Agent for Hydrogen Magnetic Resonance Imaging

A method of using an imaging contrast agent is provided for hydrogen magnetic resonance imaging (H MRI). The agent uses replacement and chemical exchange of hydrogen (H) and deuterium (D) on obtaining MRI images for comparison. An isotonic physiologic saline solution with deuterium oxide (D 2 O) is made. The solution is intravenously injected to obtain the intensity alterations on MRI images. The injected D 2 O is perfused into tissue and replaces the original water. Exchanges between H and D occur and a solution of hydrogen deuterium oxide (HDO) is obtained. After such mechanisms, MRI images are compared for differences. Thus, a novel, non-radioactive, non-toxic and non-invasive MRI agent is provided for people who are allergic to general imaging agents.

Tetanus Toxoid and CCL3 Improve DC Vaccines

Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4 T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy. 2haemophilus. The method of wherein the first immunogen is selected from the group consisting of tetanus toxoid claim 1 , diphtheria toxoid claim 1 , tetanus-diphtheria toxoids claim 1 , pneumococcal conjugate vaccine (PCV) claim 1 , and b conjugate vaccine.3. The method of wherein the first and second administrations are separated by 6 to 72 hours.4. The method of wherein the first and second administrations are separated by 24 to 48 hours.5. The method of wherein the first immunogen induces production of CCL3.6. The method of wherein the first immunogen expands CD4+ T cell memory.7. The method of wherein the second immunogen comprises a tumor-associated or tumor-specific antigen or peptide.8. The method of wherein the second immunogen comprises an antigen of an infectious agent.9. The method of wherein the second immunogen comprises a dendritic cell vaccine.10. The method of wherein the second immunogen comprises an antigen-pulsed dendritic cell vaccine.11. The method of wherein the second immunogen comprises dendritic cells pulsed with a CMV integument protein pp65 RNA.12. The method of wherein the human has a cancer.13. The method of wherein the human has a glioblastoma ...

Pharmaceutical Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes

Sterile and non-toxic pharmaceutical compositions of near IR, closed chain, sulfo-cyanine dyes and methods for visualizing tissue under illumination with near-infrared radiation are provided. 4. The composition of claim 1 , wherein the composition unit dosage form is 0.05 claim 1 , 0.10 claim 1 , 0.20 claim 1 , 0.30 claim 1 , 0.35 claim 1 , 0.40 claim 1 , 0.45 claim 1 , 0.50 claim 1 , 0.55 claim 1 , 0.60 claim 1 , 0.65 claim 1 , 0.70 claim 1 , 0.75 claim 1 , 0.80 claim 1 , 0.90 claim 1 , 1 claim 1 , 2 claim 1 , 4 claim 1 , 6 claim 1 , or 8 mg/kg.5. The composition of where the composition is adapted for administration to a human patient to obtain visualization of human tissue under illumination with near-infrared radiation wherein the unit dosage form is between 0.05 and 8 mg/kg.6. The composition of where the composition is dry and a single dose form.7. The composition of where the composition is lyophilized in a sterile container.8. The composition of where the composition is contained within a sterile container claim 1 , where the container has a machine detectable identifier which is readable by a medical device.9. The composition of further comprising combination with pharmaceutically acceptable excipients in an oral dosage form.10. The composition of further comprising combination with pharmaceutically acceptable carriers in an injectable dosage form.11. The composition of further comprising combination with pharmaceutically acceptable excipients in a dosage form for direct application to a surgical site. The present application is a Divisional of U.S. patent application Ser. No. 14/937,641 filed Nov. 10, 2015 (Allowed); the full disclosure which is incorporated herein by reference in its entirety for all purposes.Minimally invasive medical techniques are intended to reduce the amount of extraneous tissue that is damaged during diagnostic or surgical procedures, thereby reducing patient recovery time, discomfort, and deleterious side effects. While millions of ...

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Ascorbate formulations and methods of use as contrast agents

A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.

IMAGING PHANTOM AND SYSTEMS AND METHODS OF USING SAME

An imaging phantom having a housing and a dynamic perfusion assembly positioned within the housing. The dynamic perfusion assembly permits the flow of at least one contrast agent into a non-contrast solution at a desired rate. The dynamic perfusion assembly includes a first chamber that receives at least one contrast agent and a second chamber that receives a non-contrast solution. The second chamber receives the at least one contrast agent from the first chamber at the desired rate. 1. An imaging phantom comprising:a housing; and a first chamber configured to receive at least one contrast agent; and', 'a second chamber configured to receive a non-contrast solution, and wherein the second chamber is configured to receive the at least one contrast agent from the first chamber at the desired rate., 'a dynamic perfusion assembly positioned within the housing and configured to permit the flow of at least one contrast agent into a non-contrast solution at a desired rate, wherein the dynamic perfusion assembly comprises2. The imaging phantom of claim 1 , wherein the dynamic perfusion assembly is configured to maintain a substantially constant temperature within the first and second chambers.3. The imaging phantom of claim 1 , further comprising a static chamber positioned within the housing and configured to receive a liquid mixture of a non-contrast solution and at least one contrast agent claim 1 , wherein the static chamber is configured to maintain a concentration of the at least one contrast agent within the liquid mixture.4. The imaging phantom of claim 1 , wherein the dynamic perfusion assembly further comprises a semi-permeable membrane positioned between and in fluid communication with the first chamber and the second chamber.511-. (canceled)12. The imaging phantom of claim 3 , wherein the imaging phantom is configured for positioning within a bore of an MRI scanner.13. The imaging phantom of claim 12 , wherein the first chamber of the dynamic perfusion assembly ...

Pharmaceutical formulations

The invention provides a pharmaceutical composition comprising (a) a compound of the formula (1), wherein R 1 , R 2 , R 3 and R 4 are substituents, at least one of which contains a carborane cluster; and M is selected from two hydrogen ions and one or two metal ions, wherein any metal ions present are charge-balanced by one or more counter ions; and (b) a vehicle comprising: (i) dimethylacetamide as solvent; and (ii) a co-solvent comprising one or more of tetraglycol; propylene glycol; polyethylene glycol; and a non-ionic surfactant. The pharmaceutical compositions are useful as radiation sensitizers in radiation treatment of cancers.

ESTROGEN THERAPY FOR BRAIN GRAY MATTER ATROPHY AND ASSOCIATED DISABILITY

Provided are methods for slowing, halting, and reversing gray matter atrophy and progression of disability in certain neurodegenerative diseases, including multiple sclerosis, using estrogen, alone or in combination with another agent. 1. A method of (a) slowing , reversing , or halting gray matter atrophy; (b) slowing , reversing , or halting the progression of disability; (c) slowing , reversing , or halting the progression of memory loss; or (d) slowing , reversing , or halting the progression of a learning disability in a neurodegenerative disease patient , comprising administering to the patient an estrogen.26-. (canceled)7. The method of claim 1 , wherein the neurodegenerative disease is Alzheimer's disease claim 1 , Parkinson's disease claim 1 , multiple sclerosis claim 1 , relapse-remitting multiple sclerosis claim 1 , secondary-progressive multiple sclerosis claim 1 , primary-progressive multiple sclerosis claim 1 , progressive-relapsing multiple sclerosis claim 1 , stroke claim 1 , amyotrophic lateral sclerosis claim 1 , cerebellar ataxia claim 1 , frontotemporal dementia claim 1 , prion disease claim 1 , Huntington's disease claim 1 , cerebral ischemia claim 1 , cerebral dementia syndrome claim 1 , infection-induced neurodegeneration disorders (e.g. claim 1 , AIDS-encephalopathy claim 1 , Creutzfeld-Jakob disease claim 1 , encephalopathies induced by rubiola and herpes viruses and borrelioses) claim 1 , metabolic-toxic neurodegenerative disorders (such as hepatic- claim 1 , alcoholic- claim 1 , hypoxic- claim 1 , hypo- or hyperglycemically-induced encephalopathies) claim 1 , encephalopathies induced by solvents or pharmaceuticals claim 1 , trauma-induced brain damage claim 1 , or spinal cord injury.812-. (canceled)13. The method of claim 1 , wherein the estrogen is estriol.1415-. (canceled)16. The method of claim 1 , wherein administering estrogen to the patient comprises administering to the patient claim 1 , on a continuous basis throughout one or more ...

MAGNETIC APPARATUS

An imaging apparatus for imaging a sample includes a magnetic apparatus that defines a sample volume that is large enough to accommodate the sample to be imaged, and one or more magnetically manipulatable materials within the sample. The magnetic apparatus includes a magnet that is configured to create a magnetic field having a magnitude B in the sample Each magnetically manipulatable material is a material that exhibits a transition between a first magnetic state and a second magnetic state in response to a change in a property associated with the sample while the magnetic field having the magnitude B is maintained in the sample. 1. An imaging apparatus for imaging a sample , the apparatus comprising:a magnetic apparatus that defines a sample volume that is large enough to accommodate the sample to be imaged, the magnetic apparatus including a magnet that is configured to create a magnetic field having a magnitude B in the sample; andone or more magnetically manipulatable materials within the sample, each magnetically manipulatable material being a material that exhibits a transition between a first magnetic state and a second magnetic state in response to a change in a property associated with the sample while the magnetic field having the magnitude B is maintained in the sample.2. The imaging apparatus of claim 1 , further comprising an energy supply connected to the magnet claim 1 , wherein the magnet includes electrically conductive wire coils through which current from the energy supply is passed claim 1 , wherein the energy supply provides a DC current supplied to the wire coils.3. The imaging apparatus of claim 2 , wherein the magnet is a superconducting magnet.4. The imaging apparatus of claim 1 , wherein the magnetic field magnitude B is greater than 0.5 Tesla or in a range of 1-20 Tesla.5. The imaging apparatus of claim 1 , wherein the first magnetic state is an antiferromagnetic state or a paramagnetic state claim 1 , and the second magnetic state is a ...

MAGNETIC APPARATUS

An apparatus includes a magnetic apparatus that defines an actuation volume that is large enough to accommodate a sample, the magnetic apparatus including a magnet that is configured to create a magnetic field having a magnitude B in the sample when supplied with a DC current; at least one biological construct within the sample, the biological construct configured to change its status in response to a change in a property; and at least one magnetocaloric actuator coupled with the biological construct. A change in a characteristic in the actuation volume causes the property of the magnetocaloric actuator to change, which causes a change in the status of the biological construct. 1. An apparatus comprising:a magnetic apparatus that defines an actuation volume that is large enough to accommodate a sample, the magnetic apparatus including a magnet that is configured to create a magnetic field having a magnitude B in the sample when supplied with a DC current;at least one biological construct within the sample, the biological construct configured to change its status in response to a change in a property; andat least one magnetocaloric actuator coupled with the biological construct;wherein a change in a characteristic in the actuation volume causes the property of the magnetocaloric actuator to change, which causes a change in the status of the biological construct.2. The apparatus of claim 1 , wherein the sample is a region of a live human body and the magnetocaloric property changes while the temperature in the live human body region is at a human body temperature.3. The apparatus of claim 1 , wherein the change caused to the property of the magnetocaloric actuator occurs without causing a change in status of materials within the sample other than the at least one biological construct.4. The apparatus of claim 1 , further comprising an energy supply connected to the magnet claim 1 , wherein the magnet includes electrically conductive wire coils through which current ...

VIVO DETECTION OF EGFR MUTATION IN GLIOBLASTOMA VIA MRI SIGNATURE CONSISTENT WITH DEEP PERITUMORAL INFILTRATION

A method, including a computer-implemented method, is provided for in vivo detection of epidermal growth factor receptor (EGFR) mutation status within peritumoral edematous tissue of a patient. The method includes performing quantitative pattern analysis of magnetic resonance imaging (MRI) data corresponding to MRI of in vivo peritumoral edematous tissue to determine a level of spatial heterogeneity or similarity within the in vivo peritumoral edematous tissue. EGFR mutation status is assigned as one of negative or positive based on the level of spatial heterogeneity or similarity determined. A non-transitory computer-readable storage medium and a system are also provided. 1. A computer-implemented method for in vivo detection of an epidermal growth factor receptor (EGFR) mutation status within peritumoral edematous tissue , comprising executing on a processor the steps of:performing quantitative pattern analysis of magnetic resonance imaging (MRI) data corresponding to MRI of in vivo peritumoral edematous tissue to determine a level of spatial heterogeneity or similarity within the in vivo peritumoral edematous tissue; andassigning EGFR mutation status as one of negative or positive based on the level of spatial heterogeneity or similarity determined during said performing step.2. The method according to claim 1 , wherein the mutation is selected from EGFR variant III (vIII) claim 1 , a point mutation at EGFR A289V claim 1 , a point mutation at EGFR variant G598 claim 1 , and/or a point mutation at EGFR variant R108 claim 1 , with reference to the residue numbering of SEQ ID NO:1.3. The computer-implemented method according to claim 1 , wherein claim 1 , during said performing step claim 1 , spatial heterogeneity or similarity of perfusion temporal dynamics is determined within the in vivo peritumoral edematous tissue.4. The computer-implemented method according to claim 1 , wherein claim 1 , during said performing step claim 1 , imaging data of at least separate ...

CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING

Ascorbate or a pharmaceutically acceptable salt thereof is described for use in carrying out a method, or for the preparation of a medicament for carrying out a method, of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject. The method is carried out by parenterally administering ascorbate or a pharmaceutically acceptable salt thereof to the subject in an MRI image-enhancing amount; and then generating, by MRI of the subject, an image of the body or body region. The ascorbate or pharmaceutically acceptable salt thereof enhances the MRI image. 1. A method of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject , comprising:parenterally administering a composition comprising ascorbate or a pharmaceutically acceptable salt thereof to said subject in an MRI image-enhancing amount, wherein said composition comprises a spin-spin exchange catalyst; and thengenerating, by MRI of the subject, an image of said body or body region,whereby said composition enhances the MRI image.2. The method of claim 1 , wherein said body region is a head claim 1 , neck claim 1 , thorax claim 1 , abdomen claim 1 , pelvis claim 1 , limb(s) claim 1 , muscle claim 1 , fat claim 1 , or bone.3. The method of claim 1 , wherein said organ comprises an adrenal gland claim 1 , pituitary claim 1 , thymus claim 1 , corpus luteum claim 1 , retina claim 1 , brain claim 1 , spleen claim 1 , lung claim 1 , testicle claim 1 , lymph nodes claim 1 , liver claim 1 , thyroid claim 1 , small intestinal mucosa claim 1 , leukocytes claim 1 , pancreas claim 1 , kidney claim 1 , or salivary gland tissue.4. The method of claim 1 , wherein said body region is a brain.5. The method of claim 1 , wherein said body region is a heart.6. The method of claim 1 , wherein said ascorbate or pharmaceutically salt thereof is administered in an amount of from 0.02 grams per kilogram subject body ...

Process For The Preparation Of Hyperpolarized Carboxylate Compounds

The present invention relates to a process for the preparation of aqueous solutions of [1- 13 C]-hyperpolarized carboxylate containing molecules of diagnostic interest that comprises parahydrogenating with molecular para-hydrogen unsaturated alkenyl or alkynyl esters of the concerned 13 C-carboxylate molecules.

INTRADIALYTIC ADMINISTRATION OF SODIUM THIOSULFATE

The invention provides a source of sodium thiosulfate via the dialysate used to cleanse the bool of toxic and metabolic waste in the patients undergoing hemodialysis, peritoneal dialysis, or gastro-intestinal dialysis for treatment of end-stage or near end-stage chronic renal disease. In the method of the invention, dialysis solution components contain therapeutic amounts of sodium thiosulfate, which when fully reconstituted for use as a single solution, deliver 20-130 mg/dl of dialysate. 1. A method of treating dialysis dependent patients suffering from end-stage renal disease in which said patient has or is_susceptible to complications from calcification processes in the body comprising:mixing a hemodialysate solution from a dry powder mixture comprising sodium thiosulfate so that said hemodialysate solution comprises about 20 mg/dl to about 130 mg/dl sodium thiosulfate,performing hemodialysis on said dialysis dependent patient with said hemodialysate solution, and assessing said dialysis patent for reduction of calcification.2. The dialysis method of wherein said calcification processes include vascular calcification characterized by coronary ischemic events claim 1 , peripheral vascular occlusive disease claim 1 , mesenteric ischemia claim 1 , restrictive lung disease or pulmonary hypertension claim 1 , skin ulcers claim 1 , decubitous ulcers claim 1 , and other organ vascular insufficiency; myocardial claim 1 , endocardial and pericardial calcification claim 1 , calcification of the heart valves; muscular calcification; and calcification of perineurium claim 1 , endoneurium claim 1 , the vasa nervorum claim 1 , distal pre-capillary arterioles claim 1 , and soft tissue.3. The method of claim 1 , wherein said assessing said dialysis dependent patient for reduction of calcification comprises determining the coronary artery calcium score of said patient.4. The method of claim 3 , wherein said coronary artery calcium score of said patient is improved as compared to ...

MANGANESE-BASED MAGNETIC RESONANCE CONTRAST AGENTS

Manganese coordination complexes with utility as magnetic resonance probes and as biological reductant sensors are disclosed. In one embodiment, ligands can stabilize both the Mn and Mn oxidation states. In the presence of a reductant such as glutathione, low relaxivity Mn-HBET is rapidly converted to high relaxivity Mn-HBET with a 3-fold increase in relaxivity, and concomitant increase in magnetic resonance signal. In another embodiment, ligands were designed to chelate Mn(ll) in a thermodynamically stable and kinetically inert fashion while allowing for direct interaction of Mn(ll) with water. In yet another embodiment, high molecular weight multimers containing six Mn(ll) chelators were prepared. The high molecular weight results in slower tumbling of the molecules in solution and can strongly enhance the Mn(ll) relaxivity. 8. The contrast agent of wherein:{'sup': '1', 'Ris ethylene.'}9. The contrast agent of wherein:{'sup': '2', 'Ris methoxy.'}10. The contrast agent of wherein:{'sup': '2', 'Ris nitro.'}11. The contrast agent of wherein:{'sup': '1', 'Ris cyclohexylene.'}12. The contrast agent of wherein:{'sup': 1', '2, 'at least one of Rand Rcomprises a targeting moiety that can target a region of interest in a subject.'}13. The contrast agent of wherein:the targeting moiety is selected from proteins, enzymes, peptides, antibodies, and drugs.14. The contrast agent of wherein:Mn is a positron emitting manganese isotope.15. The contrast agent of wherein:the contrast agent has a higher relaxivity when n=2.16. The contrast agent of wherein:the compound is convertible in vivo from the Formula (I) wherein n=3 to the Formula (I) wherein n=2.17. The contrast agent of wherein:the compound is convertible in vivo by a biological reducing agent from the Formula (I) wherein n=3 to the Formula (I) wherein n=2.18. The contrast agent of wherein:the biological reducing agent is glutathione.19. The contrast agent of further comprising:a pharmaceutically acceptable carrier ...

Methods for the Treatment of Multiple Sclerosis

A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject. 1. A method for treating a subject with multiple sclerosis , comprisingadministering to the subject a therapeutically effective amount of an IL-2 receptor antagonist in the absence of treatment with beta interferon,wherein the subject has failed to respond to previous treatment with beta interferon,thereby ameliorating a sign or symptom of multiple sclerosis and treating the subject.2. The method of claim 1 , wherein the IL-2 receptor antagonist is administered intravenously.3. The method of claim 2 , wherein the IL-2 antagonist comprises an antibody that specifically binds the IL-2 receptor.4. The method of claim 3 , wherein the antibody is a humanized monoclonal antibody.5. The method of claim 4 , wherein the antibody specifically binds p55.6. The method of claim 4 , wherein the antibody is administered at a dose of about 1 to about 3 milligrams per kilogram intravenously.7. The method of claim 4 , wherein the antibody is administered at a dose of about 1 per kilogram to about 2 milligrams per kilogram intravenously.8. The method of claim 3 , wherein the antibody is administered biweekly.9. The method of claim 1 , wherein treatment of the subject results in a decreased number of contrast enhancing-lesions as evaluated by Magnetic Resonance Imaging.10. The method of claim 1 , wherein the treatment with beta interferon comprises treatment with interferon-beta 1a.11. The method of claim 1 , wherein the treatment with beta interferon comprises treatment with interferon-beta 1b.12. The method of claim 1 , wherein the subject has relapsing-remitting multiple sclerosis.13. The method of claim 1 , ...

Contrast agents based on long-lived nuclear singlet states and related methods

Methods are described for preparing magnetic resonance imaging (MRI) and/or magnetic resonance spectroscopy contrast agents where the contrast agents are prepared from precursor molecules having at least four non-zero-spin nuclei that form two pairs of chemically equivalent or effectively equivalent nuclei, e.g., diphenylacetylene or diethyl oxalate. The precursor molecule is hyperpolarized and a sequence of one or more radiofrequency pulses is applied to transfer spin state population between the first and second pair of nuclei, thereby providing a non-equilibrium single state nuclear spin population. To detect the contrast agent, another sequence of one or more radiofrequency pulses is applied to transfer singlet order to polarization. No transformation of the molecular structure of the contrast agent is necessary for detection. Also described are methods of imaging targets using the contrast agents.

METHODS OF TREATING BRAIN DISORDERS OR IDENTIFYING BIOMARKERS RELATED THERETO

The present disclosure relates in part to methods of treating cognitive disorders and/or identifying biomarkers. 1. A method of treating a cognitive disorder or enhancing cognitive function and/or learning in a patient in need thereof , comprising:generating a MRI signal that is a measurement of brain activity in a patient;identifying the signal as a normal or abnormal brain state of the patient; andadministering to the patient an effective amount of GLYX-13 based on the signal identification.2. The method of claim 1 , wherein the generating an MRI signal comprises using functional magnetic resonance imaging.3. The method of claim 2 , wherein the functional magnetic resonance imaging comprises blood-oxygen-level dependent contrast imaging.4. The method of claim 1 , wherein the brain activity is neural activation.5. The method of claim 4 , wherein the neural activation is neural activation in learning and/or memory related regions of the brain.6. A method for identifying a biomarker related to neural activation claim 4 , learning claim 4 , or memory or identifying a patient population who is more susceptible to such disorders claim 4 , comprising:administering GLYX-13 to an animal;imaging the animal using functional magnetic resonance to create measurable activity;analyzing the activity; andidentifying the biomarker as result of the activity.7. The method of claim 6 , wherein using functional magnetic resonance to create measurable activity comprises using blood-oxygen-level dependent contrast imaging.8. The method of claim 7 , wherein the measurable activity comprises changes in blood flow and/or blood oxidation in one or more regions of the brain in the animal.9. The method of or claim 7 , wherein the biomarker is a blood-oxygen-level dependent contrast signal in one or more regions of the brain in the animal.10. The method of claim 6 , wherein the method further comprises associating a patient or subpopulation of patients with the biomarker.11. The method of claim ...

MALIGNANT TUMOR TARGET PEPTIDE

The present invention provides a peptide comprising the amino acid sequence of any of the formulas (I)-(III) below: 1. A peptide comprising the amino acid sequence of any of the following (i)-(vi):(i) an amino acid sequence of L[D] R[D] F[D] P[D] T[D]V[D] L[D],(ii) an amino acid sequence of L[D] L[D] S[D] W[D] P[D]S[D] A[D],(iii) an amino acid sequence of S[D] P[D] T[D] S[D] L[D]L[D] F[D],(iv) an amino acid sequence of M[D] P[D] T[D] L[D] T[D]F[D] R[D],(v) an amino acid sequence of any of (i)-(iv), in which 1 or several amino acids are inserted, substituted or deleted, or these are combined, and(vi) an amino acid sequence that is a Retro-inverso of the amino acid sequence of any of (i)-(v),wherein each amino acid symbol immediately followed by symbol [D] is a D form of the amino acid.2. The peptide according to claim 1 , consisting of the amino acid sequence of any of the following (i)-(vi):(i) an amino acid sequence of L[D] R[D] F[D] P[D] T[D]V[D] L[D],(ii) an amino acid sequence of L[D] L[D] S[D] W[D] P[D]S[D] A[D],(iii) an amino acid sequence of S[D] P[D] T[D] S[D] L[D]L[D] F[D],(iv) an amino acid sequence of M[D] P[D] T[D] L[D] T[D]F[D] R[D],(v) an amino acid sequence of any of (i)-(iv), in which 1 or several amino acids are inserted, substituted or deleted, or these are combined, and(vi) an amino acid sequence that is a Retro-inverso of the amino acid sequence of any of (i)-(v),wherein each amino acid symbol immediately followed by symbol [D] is a D form of the amino acid.3. A conjugate comprising the peptide according to linked to one other component.4. The conjugate according to claim 3 , wherein the one other component is an anticancer agent.5. The conjugate according to claim 4 , wherein the anticancer agent is selected from the group consisting of an antimetabolite claim 4 , an alkylating agent claim 4 , an anticancer antibiotic claim 4 , a microtubule inhibitor claim 4 , a platinum preparation claim 4 , a topoisomerase inhibitor claim 4 , a molecular ...

Multicore Magnetic Particles

A multicore magnetic particle. In one embodiment, the magnetic particle includes a plurality of superparmagnetic cores embedded in a non-magnetic matrix. In another embodiment, the effective anisotropy energy barrier of the particle is larger than the sum of the anisotropy energy barriers of the individual superparamagnetic cores. In yet another embodiment, the superparamagnetic cores are close enough to interact magnetically by exchange coupling and dipole interaction. In still yet another embodiment, the specific loss power of the magnetic particle is greater than the specific loss power of an equivalent mass of individual superparamagnetic cores. 1. A multicore magnetic particle comprising:a plurality of superparmagnetic cores embedded in a non-magnetic matrix,wherein the effective anisotropy energy barrier of the multicore magnetic particle is larger than the sum of the anisotropy energy barriers of the individual superparamagnetic cores.2. A magnetic particle comprising:a plurality of superparmagnetic cores located in a non-magnetic matrix,wherein the superparamagnetic cores are close enough to interact magnetically by exchange coupling and dipole interaction, andwherein the specific loss power of the magnetic particle is greater than the specific loss power of an equivalent mass of individual superparamagnetic cores.3. The magnetic particle of wherein the spacing between the superparamagnetic cores is less than 10 nm.4. The magnetic particle of wherein the spacing between the superparmagnetic cores is less than 5 nm.5. The magnetic particle of wherein the spacing between the superparmagnetic cores is less than 2 nm.6. The magnetic particle of wherein the superparamagnetic cores comprise maghemite.7. The magnetic particle of wherein the matrix is selected from the group consisting of carboxylic or hydroxycarboxylic acids claim 1 , mono- claim 1 , di- or polysaccharides claim 1 , synthetic or biological polymers particularly hydrophilic polymers claim 1 , ...

DETERMINATION OF STRUCTURE AND TRAVERSAL OF OCCLUSIONS USING MAGNETIC PARTICLES

This disclosure generally relates to systems and methods for facilitating determination of morphology (e.g., shape) and structure (e.g., size, rigidity) and/or penetrating channels (e.g., microchannels) of occlusions (e.g., clots, fluid obstructions, tumors, chronic total occlusions) involving magnetic particles (e.g., nanoparticles, microparticles) controlled by an external magnetic control system. 1. A method of facilitating treatment of a therapeutic target within a body of a subject , the method comprising:delivering magnetic particles to a location near the therapeutic target within the body of the subject;applying a rotating magnetic field so as to cause the magnetic particles to agglomerate into stir bars and to generate a circulating motion adjacent the therapeutic target so as to cause at least some of the magnetic particles to be driven into an outer surface of the therapeutic target; andobtaining images indicative of a shape of the surface profile of the therapeutic target using an imaging modality capable of imaging the magnetic particles.2. The method of claim 1 , wherein applying the rotating magnetic field comprises rotating a permanent magnet positioned external to the subject.3. The method of claim 2 , wherein rotating the permanent magnet comprises rotating the permanent magnet at a frequency of between 1 Hz and 10 Hz claim 2 , and wherein a magnitude of the magnetic field is between 0.01 and 1 Tesla.4. The method of claim 1 , wherein at least some of the magnetic particles comprise a diagnostic or theranostic agent.5. The method of claim 1 , further comprising delivering a therapeutic agent to the location of the therapeutic target.6. The method of claim 1 , further comprising delivering a diagnostic or theranostic agent to the location of the therapeutic target claim 1 , wherein the circulating motion of the stir rods causes at least some of the diagnostic or theranostic agent to be driven into the outer surface of the therapeutic target claim 1 ...

HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES

Systems, methods and related devices used to produce and collect polarized noble gas to inhibit, suppress, detect or filter alkali metal nanoclusters to preserve or increase a polarization level thereof. The systems can include a pre-sat chamber that has an Area Ratio between 20 and 500. 1. A pre-saturation device for a flow-through spin-exchange hyperpolarizer , comprising:a pre-saturation member having an internal pre-saturation chamber, wherein the per-saturation member is sealably attachable to a manifold of a spin-exchange hyperpolarizer upstream of an optical pumping cell, wherein the pre-saturation member has opposing first and second ends and alkali metal held in the pre-saturation chamber, prior to first use and/or prior to attachment to the manifold, in an amount between 0.5 grams and 5 grams.2. The device of claim 1 , wherein the alkali metal comprises at least one of Rb claim 1 , Cs claim 1 , Na claim 1 , and K and/or any combination thereof with a cumulative amount claim 1 , for a new and unused pre-saturation member claim 1 , being between 1-3 grams.3. The device of claim 1 , wherein the pre-saturation member is configured for attachment to the manifold of the hyperpolarizer in a sealed state to inhibit the alkali metal from being exposed to air.4. The device of claim 1 , wherein the pre-saturation member has longitudinally spaced apart end portions comprising one or more of: (i) metal seals claim 1 , (ii) valves claim 1 , and/or (iii) threaded attachment segments for sealably and releasably attaching to a pressurized fluid flow manifold as the manifold of the hyperpolarizer.5. The device of claim 1 , wherein the pre-saturation chamber has an Area Ratio (AR) of between 20 and 500.6. The device of claim 5 , wherein the AR is between 20 and 200.7. The device of claim 5 , wherein the AR is about 100.8. The device of claim 1 , wherein the pre-saturation chamber comprises a silica wick.9. The device of claim 1 , wherein the pre-saturation member comprises ...

METHOD FOR INTEGRATING LARGE SCALE BIOLOGICAL DATA WITH IMAGING

There is disclosed a method of extracting large scale biological, biochemical or molecular information about an index disease, biological state, or systems from imaging by correlating the imaging features associated with said disease, state or system with corresponding large scale biological data. 146-. (canceled)47. A method of predicting a possible prognosis , treatment outcome , or diagnosis of a patient comprising:a. imaging said patient;b. identifying radiophenotype(s) in said images of said patient; andc. diagnosing or predicting a treatment outcome or prognosis of said patient based on the presence and/or absence of said radiophenotype(s). This Application claims priority of U.S. provisional application Ser. No. 60/685,924 filed May 31, 2005 and is incorporated herein by reference.This invention relates to the field of imaging of patients; more specifically, it relates to using imaging features with corresponding large scale biological data such as gene expression or protein expression data of a patient.Biomedical imaging is a powerful tool that can provide systems-wide, real time in vivo contextual insights into biology. From the time of the first X-ray, in vivo imaging has provided a vital function for medical research and diagnosis, by permitting the clinician to assess, in real time and space, what is happening within the patient's body. In addition to nuclear medicine and MRI, other imaging methods including positron emission tomography (PET), computerized tomography (CT), ultrasonography (US), optical imaging, infrared imaging, in vivo microscopy and x-ray radiography have also been used for obtaining morphologic, metabolic and functional information of living tissues in vivo in a spatially and temporally resolved manner.For example, magnetic resonance imaging (MRI) is an imaging technique used primarily in medical settings to produce high quality images of the inside of the body. MRI is based on the absorption and emission of energy in the radio ...

NON-NUTRITIVE SWEETENERS AND POLYOLS AS IMAGING AGENTS

The present disclosure relates to magnetic resonance imaging (MRI) methods comprising (i) obtaining a baseline chemical exchange saturation transfer (CEST) MRI image of a patient, (ii) administering an effective amount of a non-nutritive sweetener to the patient, and (iii) obtaining one or more test CEST MRI image of the patient subsequent to the administering step (ii); wherein the step (i) and (iii) acquisition parameters are substantially the same. The non-nutritive sweetener may include a natural or artificial sugar alcohol, polyol, or combinations or derivatives thereof. 1. An imaging method , comprising:(i) administering an effective amount of a non-nutritive sweetener to a patient; and(ii) obtaining one or more images of said patient subsequent to administering step (i).2. A magnetic resonance imaging (MRI) method , comprising:(i) obtaining a baseline chemical exchange saturation transfer (CEST) MRI image of a patient;(ii) administering an effective amount of a non-nutritive sweetener to said patient; and(iii) obtaining one or more test CEST MRI images of said patient subsequent to the administration of step (ii),wherein the step (i) and (iii) acquisition parameters are substantially the same.3. The magnetic resonance imaging method of claim 2 , further comprising:(iv) comparing the baseline CEST MRI image to at least one test CEST MRI image to obtain a final image.4. The magnetic resonance imaging method of claim 2 , wherein step (i) further comprises obtaining a baseline conventional MRI image of said patient.5. The magnetic resonance imaging method of claim 2 , wherein step (iii) further comprises obtaining one or more test conventional MRI images of said patient.6. (canceled)7. (canceled)8. The magnetic resonance imaging method of claim 2 , wherein said non-nutritive sweetener is a sugar alcohol or polyol.9. The magnetic resonance imaging method of claim 8 , wherein said sugar alcohol is sorbitol claim 8 , xylitol claim 8 , erythritol claim 8 , mannitol ...